JOURNAL == O
OF == O
ADVANCED == O
VETERINARY == O
AND == O
ANIMAL == O
RESEARCH == O
A == O
periodical == O
JOURNAL  OF  ADVANCED VETERINARY AND ANIMAL RESEARCH A periodical of == O
the == O
Network == O
for == O
the == O
Veterinarians == MISC
of == O
Bangladesh == COUNTRY
( == O
BDvetNET == O
) == O
VOL == O
of the Network for the Veterinarians of Bangladesh (BDvetNET) VOL 7 == NUMBER
, == O
NO == O
. == O
2 == NUMBER
, == O
PAGES == O
198208 == NUMBER
REVIEW == O
ARTICLE == O
The == O
emergence == O
of == O
novel == O
7,  NO.  2,  PAGES  198208  REVIEW ARTICLE The emergence of novel coronavirus == O
disease == CAUSE_OF_DEATH
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
in == O
Bangladesh == COUNTRY
: == O
Present == DATE
status == O
, == O
coronavirus disease (COVID‐19)  in  Bangladesh:  Present  status, challenges == O
, == O
and == O
future == DATE
management == O
Mohammad == PERSON
Shah == PERSON
Alam1 == O
, == O
Mohammad == PERSON
challenges,  and  future management Mohammad Shah Alam1, Mohammad Zahangeer == O
Alam2 == O
, == O
K. == PERSON
H. == PERSON
M. == PERSON
Nazmul == PERSON
Hussain == PERSON
Nazir3 == O
, == O
Md == STATE_OR_PROVINCE
. == O
Abdullahil == PERSON
Zahangeer Alam2, K. H. M. Nazmul Hussain Nazir3,  Md.  Abdullahil Baki == PERSON
Bhuiyan4 == O
ARTICLE == O
HISTORY == O
Immediate == O
after == O
the == O
official == O
decla == O
Baki Bhuiyan4 ARTICLE HISTORY Immediate after the official decla ration == O
of == O
COVID == O
‐ == O
19 == NUMBER
in == O
Bangladesh == COUNTRY
on == O
8 == DATE
March == DATE
2020 == DATE
, == O
it == O
has == O
created == O
ration of COVID‐19 in Bangladesh on 8 March 2020, it has  created public == O
panic == O
which == O
results == O
in == O
price == O
plummeting == O
of == O
the == O
capital == O
public  panic  which  results  in price plummeting of the capital market == O
and == O
price == O
hike == O
of == O
many == O
essential == O
commodities == O
. == O
Worldwide == O
, == O
market and price hike of many essential  commodities.  Worldwide, the == O
outbreak == O
of == O
COVID == O
‐ == O
19 == NUMBER
has == O
declared == O
a == O
pandemic == O
. == O
In == O
response == O
, == O
the  outbreak  of  COVID‐19 has declared a pandemic. In response, the == O
Government == O
of == O
Bangladesh == COUNTRY
has == O
initiated == O
some == O
strict == O
measures == O
the Government of Bangladesh has initiated some  strict  measures such == O
as == O
stopping == O
the == O
entry == O
of == O
passengers == O
from == O
Europe == LOCATION
, == O
stopping == O
such  as  stopping  the entry of passengers from Europe, stopping on == O
‐ == O
arrival == O
visas == O
and == O
self == O
‐ == O
quarantine == O
for == O
2 == DURATION
weeks == DURATION
for == O
all == O
passen == O
‐ == O
on‐arrival visas and self‐quarantine for 2 weeks for all  passen‐ gers == O
return == O
from == O
abroad == O
. == O
Still == O
, == O
many == O
loopholes == O
exist == O
at == O
the == O
entry == O
gers return from abroad. Still, many loopholes exist at the entry points == O
of == O
Bangladesh == COUNTRY
. == O
Most == O
of == O
the == O
people == O
of == O
Bangladesh == COUNTRY
are == O
yet == O
to == O
points of Bangladesh. Most of the people of Bangladesh are yet to aware == O
of == O
the == O
consequences == O
of == O
COVID == O
‐ == O
19 == NUMBER
. == O
In == O
this == O
backdrop == O
, == O
this == O
aware  of  the  consequences  of COVID‐19. In this backdrop, this would == O
be == O
helpful == O
to == O
undertake == O
future == DATE
management == O
practices == O
against == O
would be helpful to undertake future management practices against the == O
fearsome == O
COVID == O
‐ == O
19 == NUMBER
in == O
Revised == O
March == DATE
17 == DATE
, == DATE
2020 == DATE
The == O
coronavirus == O
the  fearsome  COVID‐19 in Revised March 17, 2020 The coronavirus was == O
first == ORDINAL
isolated == O
in == O
1937 == DATE
, == O
which == O
caused == O
bronchitis == CAUSE_OF_DEATH
in == O
birds == O
was first isolated in 1937,  which  caused  bronchitis  in  birds [ == O
1,2 == NUMBER
] == O
. == O
However == O
, == O
human == O
coronaviruses == O
( == O
HCoV == O
‐ == O
229E == O
and == O
HCoV == O
‐ == O
OC43 == O
) == O
[1,2].  However,  human  coronaviruses  (HCoV‐229E and HCoV‐OC43) were == O
first == ORDINAL
characterized == O
in == O
the == DATE
1960s == DATE
[ == O
3 == NUMBER
] == O
, == O
which == O
were == O
associated == O
were first characterized in the 1960s [3], which were  associated with == O
diseases == CAUSE_OF_DEATH
in == O
respiratory == O
tracts == O
such == O
as == O
bronchitis == CAUSE_OF_DEATH
and == O
pneu == O
‐ == O
with  diseases in respiratory tracts such as bronchitis and pneu‐ monia == O
and == O
illnesses == O
in == O
the == O
enteric == O
and == O
central == O
nervous == O
system == O
monia and illnesses in the enteric  and  central  nervous  system [ == O
3,4 == NUMBER
] == O
. == O
The == O
virus == O
is == O
named == O
as == O
coronavirus == O
for == O
the == O
crown == O
‐ == O
like == O
[3,4].  The  virus  is  named  as  coronavirus for the crown‐like spikes == O
on == O
their == O
surface == O
[ == O
5 == NUMBER
] == O
. == O
According == O
to == O
the == O
Centers == O
for == O
Disease == CAUSE_OF_DEATH
spikes on their surface [5]. According to the Centers for Disease Control == ORGANIZATION
and == ORGANIZATION
Prevention == ORGANIZATION
, == O
Atlanta == CITY
, == O
USA == COUNTRY
, == O
the == O
syndrome == O
of == O
coronavirus == O
Control and Prevention, Atlanta, USA, the syndrome of coronavirus is == O
called == O
severe == O
acute == O
respiratory == O
syndrome == O
( == O
SARS == O
) == O
. == O
The == O
virus == O
is called severe acute respiratory  syndrome  (SARS).  The  virus SARS == O
‐ == O
associated == O
coronavirus == O
( == O
SARS == O
‐ == O
CoV == O
) == O
has == O
received == O
worldwide == O
at == O
‐ == O
SARS‐associated coronavirus (SARS‐CoV) has received worldwide at‐ tention == O
due == O
to == O
its == O
epidemic == O
appearance == O
in == O
2003 == DATE
. == O
Since == O
then == O
, == O
a == O
to == O
‐ == O
tention due to its epidemic appearance in 2003. Since then, a to‐ tal == O
of == O
8,098 == NUMBER
people == O
became == O
sick == O
, == O
which == O
claimed == O
774 == NUMBER
lives == O
across == O
tal  of  8,098 people became sick, which claimed 774 lives across the == O
globe == O
[ == O
6 == NUMBER
] == O
. == O
However == O
, == O
there == O
were == O
no == O
known == O
cases == O
of == O
SARS == O
report == O
‐ == O
the globe [6]. However, there were no known cases of SARS report‐ ed == O
anywhere == O
in == O
the == O
world == O
Correspondence == O
Md == STATE_OR_PROVINCE
. == O
Abdullahil == PERSON
Baki == PERSON
ed  anywhere  in  the  world  Correspondence  Md. Abdullahil Baki Bhuiyan == O
Coronavirus == O
; == O
outbreak == O
; == O
fatality == O
; == O
pneumonia == CAUSE_OF_DEATH
; == O
Bangladesh == COUNTRY
Bhuiyan Coronavirus; outbreak;  fatality;  pneumonia;  Bangladesh distributed == O
under == O
the == O
terms == O
of == O
the == O
after == O
2004 == DATE
[ == O
7 == NUMBER
] == O
. == O
Recently == DATE
, == O
a == O
distributed  under  the  terms of the after 2004 [7]. Recently, a novel == O
coronavirus == O
named == O
SARSCoV == O
‐ == O
2 == NUMBER
has == O
spread == O
worldwide == O
[ == O
8 == NUMBER
] == O
, == O
in == O
‐ == O
novel coronavirus named SARSCoV‐2 has spread worldwide  [8],  in‐ cluding == O
Bangladesh == COUNTRY
, == O
which == O
is == O
one == NUMBER
of == O
the == O
most == O
densely == O
populated == O
cluding  Bangladesh,  which  is one of the most densely populated countries == O
( == O
160 == NUMBER
million == NUMBER
) == O
in == O
the == O
world == O
[ == O
9 == NUMBER
] == O
. == O
Although == O
overpopulated == O
, == O
countries (160 million) in the world [9]. Although overpopulated, the == O
economy == O
of == O
Bangladesh == COUNTRY
is == O
booming == O
in == O
recent == O
times == O
[ == O
8 == NUMBER
] == O
. == O
Since == O
the  economy  of Bangladesh is booming in recent times [8]. Since its == O
independence == O
in == O
1971 == DATE
, == O
the == O
annual == SET
gross == O
domestic == O
product == O
in == O
its independence in 1971, the annual gross  domestic  product  in Bangladesh == COUNTRY
was == O
8.75 == MONEY
billion == MONEY
, == O
which == O
is == O
expected == O
to == O
reach == O
315.00 == NUMBER
Bangladesh  was  8.75  billion, which is expected to reach 315.00 billion == NUMBER
USD == O
by == O
the == DATE
end == DATE
of == DATE
2020 == DATE
[ == O
8 == NUMBER
] == O
. == O
In == O
this == O
situation == O
, == O
the == O
emer == O
‐ == O
billion USD by the end of 2020 [8]. In this situation, the  emer‐ gence == O
of == O
novel == O
coronavirus == O
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
in == O
Bangladesh == COUNTRY
could == O
be == O
a == O
gence  of  novel  coronavirus (COVID‐19) in Bangladesh could be a threat == O
to == O
the == O
boosting == O
economy == O
. == O
Taxonomy == O
, == O
types == O
, == O
origin == O
and == O
evo == O
‐ == O
threat to the boosting economy.  Taxonomy, types, origin and evo‐ lution == O
of == O
human == O
Coronaviruses == MISC
( == O
CoVs == O
) == O
belong == O
to == O
the == O
family == O
Coron == O
‐ == O
lution  of human Coronaviruses (CoVs) belong to the family Coron‐ aviridae == O
under == O
order == O
Nidovirales == O
. == O
The == O
family == O
Coronoviridae == O
has == O
aviridae under order Nidovirales. The  family  Coronoviridae  has two == NUMBER
How == O
to == O
cite == O
: == O
Alam == O
MS == STATE_OR_PROVINCE
, == O
Alam == O
MZ == O
, == O
Nazir == PERSON
KHMNH == PERSON
, == O
Bhuiyan == PERSON
MAB == PERSON
. == O
The == O
two  How to cite: Alam MS, Alam MZ, Nazir KHMNH, Bhuiyan MAB. The emergence == O
of == O
novel == O
coronavirus == O
disease == CAUSE_OF_DEATH
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
in == O
Bangladesh == COUNTRY
: == O
emergence of novel coronavirus disease (COVID‐19) in  Bangladesh: Present == DATE
status == O
, == O
challenges == O
and == O
future == DATE
management == O
. == O
J == PERSON
Adv == PERSON
Vet == PERSON
Anim == PERSON
Present  status, challenges and future management. J Adv Vet Anim Res == O
2020 == DATE
; == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
. == O
Res 2020; 7(2):198208. Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam et al./ J. Adv. Vet. Anim. Res., 7(2):  198208,  June  2020 subfamilies == O
, == O
such == O
as == O
Orthocoronaviridae == O
and == O
Torovirinae == O
. == O
The == O
subfamilies,  such  as  Orthocoronaviridae  and Torovirinae.  The subfamily == O
Orthocoronaviridae == O
has == O
four == NUMBER
genera == O
, == O
such == O
as == O
alphacoron == O
‐ == O
subfamily Orthocoronaviridae has four genera, such as alphacoron‐ avirus == O
, == O
betacoronavirus == O
, == O
gammacoronavirus == O
and == O
deltacoronavirus == O
avirus,  betacoronavirus,  gammacoronavirus  and deltacoronavirus [ == O
10 == NUMBER
] == O
. == O
Until == O
now == DATE
, == O
seven == NUMBER
types == O
of == O
coronaviruses == O
have == O
the == O
ability == O
to == O
[10]. Until now, seven types of coronaviruses have the ability to infect == O
human == O
. == O
The == O
human == O
coronaviruses == O
are == O
229E == O
, == O
NL63 == O
, == O
OC43 == O
and == O
infect  human.  The  human coronaviruses are 229E, NL63, OC43 and HKU1 == O
, == O
and == O
the == O
rarer == O
strains == O
are == O
SARS == O
‐ == O
CoV == O
[ == O
11 == NUMBER
] == O
and == O
Middle == O
Eastern == O
HKU1, and the rarer strains are SARS‐CoV [11] and Middle  Eastern respiratory == O
syndrome == O
coronavirus == O
( == O
MERS == O
‐ == O
CoV == O
) == O
which == O
was == O
first == ORDINAL
ap == O
‐ == O
respiratory  syndrome  coronavirus (MERS‐CoV) which was first ap‐ peared == O
in == O
2012 == DATE
in == O
Saudi == COUNTRY
Arabia == COUNTRY
[ == O
12 == NUMBER
] == O
and == O
recent == O
SARSCoV == O
‐ == O
2 == NUMBER
[ == O
13 == NUMBER
] == O
. == O
peared in 2012 in Saudi Arabia [12] and  recent  SARSCoV‐2  [13]. The == O
virus == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
has == O
a == O
single == O
‐ == O
stranded == O
RNA == O
genome == O
ranged == O
from == O
The virus SARS‐CoV‐2 has a single‐stranded RNA genome ranged from 26 == NUMBER
to == O
32 == NUMBER
kilobases == O
( == O
kb == O
) == O
in == O
length == O
, == O
which == O
is == O
one == NUMBER
of == O
the == O
largest == O
26 to 32 kilobases (kb) in length, which is one  of  the  largest genomes == O
among == O
RNA == O
viruses == O
[ == O
14 == NUMBER
] == O
. == O
Ten == NUMBER
genome == O
sequences == O
of == O
SARS == O
‐ == O
genomes  among  RNA  viruses  [14]. Ten genome sequences of SARS‐ Cov == O
‐ == O
2 == NUMBER
exhibited == O
88 == PERCENT
% == PERCENT
identity == O
with == O
two == NUMBER
bat == O
‐ == O
derived == O
SARS == O
‐ == O
like == O
coro == O
‐ == O
Cov‐2 exhibited 88% identity with two bat‐derived SARS‐like coro‐ naviruses == O
, == O
bat == O
‐ == O
SL == O
‐ == O
CoVZC45 == O
and == O
bat == O
‐ == O
SL == O
‐ == O
CoVZXC21 == O
; == O
however == O
, == O
they == O
were == O
naviruses, bat‐SL‐CoVZC45 and bat‐SL‐CoVZXC21; however, they were more == O
distant == O
from == O
SARS == O
‐ == O
CoV == O
( == O
about == O
79 == PERCENT
% == PERCENT
) == O
and == O
MERSCoV == O
about == O
50 == PERCENT
% == PERCENT
more distant from SARS‐CoV (about  79%)  and  MERSCoV  about  50% [ == O
15 == NUMBER
] == O
. == O
Usually == O
, == O
the == O
CoVs == O
are == O
commonly == O
harbored == O
in == O
mammals == O
and == O
[15].  Usually,  the  CoVs  are  commonly harbored in mammals and birds == O
as == O
well == O
as == O
in == O
camels == O
, == O
cattle == O
, == O
cats == O
, == O
bats == O
, == O
and == O
other == O
animals == O
birds as well as in camels, cattle, cats, bats, and other animals [ == O
10 == NUMBER
] == O
. == O
Genomic == O
characterization == O
of == O
SARS == O
‐ == O
CoV == O
, == O
MERS == O
‐ == O
CoV == O
, == O
and == O
SARS == O
‐ == O
[10].  Genomic  characterization of SARS‐CoV, MERS‐CoV, and SARS‐ CoV == O
‐ == O
2 == NUMBER
reported == O
that == O
the == O
origination == O
of == O
these == O
viruses == O
was == O
bats == O
. == O
CoV‐2 reported that the origination of these  viruses  was  bats. The == O
intermediate == O
hosts == O
of == O
SARS == O
‐ == O
CoV == O
and == O
MERS == O
‐ == O
CoV == O
were == O
masked == O
palm == O
The  intermediate hosts of SARS‐CoV and MERS‐CoV were masked palm civets == O
and == O
dromedary == O
camels == O
, == O
respectively == O
, == O
with == O
human == O
as == O
terminal == O
civets and dromedary camels, respectively, with human as terminal hosts == O
[ == O
16 == NUMBER
] == O
. == O
However == O
, == O
the == O
intermediate == O
hosts == O
of == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
are == O
hosts  [16].  However,  the  intermediate hosts of SARS‐CoV‐2 are predicted == O
to == O
be == O
the == O
unknown == O
wild == O
animals == O
sold == O
at == O
the == O
seafood == O
mar == DATE
‐ == O
predicted to be the unknown wild animals sold at the seafood mar‐ ket == O
[ == O
16,17 == NUMBER
] == O
. == O
Worldwide == O
severity == O
and == O
outbreak == O
of == O
novel == O
human == O
ket  [16,17].   Worldwide  severity  and  outbreak of novel human coronavirus == O
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
A == O
new == O
type == O
of == O
pneumonia == CAUSE_OF_DEATH
was == O
detected == O
in == O
coronavirus (COVID‐19) A new type of pneumonia  was  detected  in Wuhan == CITY
city == O
, == O
Hubei == STATE_OR_PROVINCE
Province == COUNTRY
of == COUNTRY
China == COUNTRY
, == O
on == O
31 == DATE
December == DATE
2019 == DATE
. == O
Since == O
Wuhan  city,  Hubei Province of China, on 31 December 2019. Since then == O
, == O
a == O
total == O
of == O
44 == NUMBER
cases == O
with == O
an == O
unknown == O
type == O
of == O
pneumonia == CAUSE_OF_DEATH
were == O
then, a total of 44 cases with an unknown type of pneumonia  were detected == O
until == O
3 == DATE
January == DATE
2020 == DATE
[ == O
18,19 == NUMBER
] == O
. == O
The == O
outbreak == O
of == O
this == O
pneu == O
‐ == O
detected until 3 January 2020 [18,19]. The outbreak of this pneu‐ monia == O
was == O
associated == O
with == O
exposures == O
in == O
one == NUMBER
seafood == O
market == O
. == O
The == O
monia was associated with exposures in one  seafood  market.  The unknown == O
case == O
was == O
confirmed == O
as == O
a == O
new == O
type == O
of == O
coronavirus == O
on == O
7 == DATE
Jan == DATE
‐ == O
unknown case was confirmed as a new type of coronavirus on 7 Jan‐ uary == O
2020 == DATE
. == O
Outside == O
of == O
China == COUNTRY
, == O
the == O
same == O
kind == O
of == O
novel == O
coronavirus == O
uary 2020. Outside of China, the same kind of  novel  coronavirus was == O
identified == O
on == O
13 == NUMBER
, == O
15 == NUMBER
, == O
and == NUMBER
20 == NUMBER
January == DATE
2020 == DATE
in == O
Thailand == COUNTRY
, == O
Japan == COUNTRY
, == O
was identified on 13, 15, and 20 January 2020 in Thailand, Japan, and == O
the == O
Health == ORGANIZATION
Organization == ORGANIZATION
[ == O
20 == NUMBER
] == O
, == O
the == O
cases == O
in == O
Thailand == COUNTRY
, == O
Japan == COUNTRY
, == O
and the Health Organization [20], the cases in  Thailand,  Japan, City == O
, == O
China == COUNTRY
. == O
Officially == O
, == O
the == O
WHO == ORGANIZATION
has == O
named == O
the == O
novel == O
coronavirus == O
City,  China. Officially, the WHO has named the novel coronavirus as == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
causing == O
coronavirus == O
disease == CAUSE_OF_DEATH
‐ == O
2019 == DATE
confirmed == O
case == O
( == O
a == O
as SARS‐CoV‐2 causing coronavirus disease‐2019 confirmed case  (a person == O
with == O
laboratory == O
confirmation == O
) == O
of == O
COVID == O
‐ == O
19 == NUMBER
was == O
282 == NUMBER
( == O
claimed == O
person with laboratory confirmation) of COVID‐19 was 282 (claimed six == NUMBER
lives == O
) == O
, == O
which == O
had == O
skyrocketed == O
to == O
153,517 == NUMBER
( == O
claimed == O
5735 == NUMBER
lives == O
) == O
six lives), which had skyrocketed to 153,517 (claimed 5735 lives) on == O
15 == DATE
March == DATE
2020 == DATE
( == O
Fig. == O
1 == NUMBER
) == O
. == O
Due == O
to == O
the == O
severe == O
outbreak == O
across == O
the == O
on  15 March 2020 (Fig. 1). Due to the severe outbreak across the globe == O
, == O
the == O
WHO == ORGANIZATION
declared == O
the == O
outbreak == O
of == O
COVID == O
‐ == O
19 == NUMBER
is == O
pandemic == O
on == O
globe, the WHO declared the outbreak of COVID‐19 is  pandemic  on 11 == DATE
March == DATE
2020 == DATE
[ == O
8 == NUMBER
] == O
. == O
11 March 2020 [8]. Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 According == O
to == O
the == O
current == DATE
WHO == O
report == O
, == O
the == O
total == O
fatality == O
of == O
According to the  current  WHO  report,  the  total  fatality  of COVID == O
‐ == O
19 == NUMBER
is == O
5,735 == NUMBER
with == O
a == O
fatality == O
rate == O
of == O
only == O
3.73 == PERCENT
% == PERCENT
[ == O
8 == NUMBER
] == O
. == O
Howev == O
‐ == O
COVID‐19 is 5,735 with a fatality rate of only 3.73% [8].  Howev‐ er == O
, == O
overall == O
mortality == O
combinedly == O
caused == O
by == O
SARSCoV == O
and == O
MERS == O
‐ == O
CoV == O
er, overall mortality combinedly caused by SARSCoV  and  MERS‐CoV was == O
1632 == DATE
[ == O
21,22 == NUMBER
] == O
, == O
with == O
the == O
rate == O
of == O
occurrence == O
of == O
9.6 == PERCENT
% == PERCENT
[ == O
23 == NUMBER
] == O
and == O
was  1632  [21,22],  with the rate of occurrence of 9.6% [23] and 35.2 == PERCENT
% == PERCENT
[ == O
2 == NUMBER
] == O
, == O
respectively == O
. == O
When == O
recorded == O
every == SET
day == SET
; == O
therefore == O
, == O
the == O
35.2% [2], respectively. When recorded every day; therefore,  the mortality == O
rate == O
of == O
COVID19 == O
might == O
be == O
changing == O
, == O
which == O
could == O
not == O
be == O
mortality  rate  of COVID19 might be changing, which could not be calculated == O
accurately == O
until == O
the == O
end == O
of == O
this == O
outbreak == O
. == O
The == O
out == O
‐ == O
calculated accurately until the end of this outbreak.   The  out‐ break == O
of == O
COVID == O
‐ == O
19 == NUMBER
and == O
its == O
consequence == O
in == O
Three == NUMBER
confirmed == O
cases == O
of == O
break of COVID‐19 and its consequence in Three confirmed cases of COVID == O
‐ == O
19 == NUMBER
announced == O
for == O
the == O
of == O
epidemiology == O
, == O
disease == CAUSE_OF_DEATH
control == O
, == O
and == O
COVID‐19 announced for the of epidemiology, disease control,  and research == O
( == O
IEDCR == O
) == O
. == O
Subsequently == O
, == O
there == O
were == O
no == O
confirmed == O
cases == O
research  (IEDCR).   Subsequently,  there were no confirmed cases found == O
on == O
13 == DATE
March == DATE
2020 == DATE
. == O
However == O
, == O
on == O
14 == DATE
March == DATE
2020 == DATE
, == O
two == NUMBER
more == O
con == O
‐ == O
found on 13 March 2020. However, on 14 March 2020, two more  con‐ firmed == O
cases == O
newly == O
detected == O
in == O
Bangladesh == COUNTRY
. == O
Until == O
now == DATE
, == O
COVID == O
‐ == O
19 == NUMBER
firmed  cases  newly  detected in Bangladesh. Until now, COVID‐19 caused == O
no == O
fatality == O
in == O
Bangladesh == COUNTRY
. == O
Among == O
the == O
and == O
Spain == COUNTRY
ranked == O
2nd == ORDINAL
, == O
caused no fatality in Bangladesh. Among the and Spain ranked 2nd, 3rd == ORDINAL
, == O
4th == ORDINAL
, == O
and == ORDINAL
5th == ORDINAL
, == O
respectively == O
, == O
after == O
China == COUNTRY
[ == O
8 == NUMBER
] == O
( == O
Fig. == O
2 == NUMBER
) == O
. == O
In == O
3rd,  4th,  and  5th,  respectively, after China [8] (Fig. 2). In comparison == O
to == O
the == O
global == O
perspective == O
, == O
although == O
the == O
occurrence == O
of == O
comparison to the global perspective, although the occurrence  of COVID == O
‐ == O
19 == NUMBER
is == O
very == O
low == O
( == O
only == O
0.003 == PERCENT
% == PERCENT
) == O
in == O
Bangladesh == COUNTRY
, == O
the == O
panic == O
which == O
COVID‐19 is very low (only 0.003%) in Bangladesh, the panic which spreads == O
among == O
the == O
most == O
densely == O
populated == O
country == O
( == O
160 == NUMBER
million == NUMBER
spreads among the most densely  populated  country  (160  million people == O
) == O
in == O
the == O
world == O
is == O
immense == O
. == O
The == O
first == ORDINAL
blow == O
of == O
this == O
panic == O
people)  in  the  world  is immense. The first blow of this panic hits == O
into == O
the == O
Bangladesh == COUNTRY
stock == O
market == O
; == O
due == O
to == O
the == O
fear == O
selling == O
, == O
hits into the Bangladesh stock market; due to the  fear  selling, the == O
general == TITLE
index == O
of == O
the == O
DSE == ORGANIZATION
plunged == O
279.32 == NUMBER
points == O
( == O
6.51 == PERCENT
% == PERCENT
) == O
to == O
the  general  index  of  the DSE plunged 279.32 points (6.51%) to close == O
the == DATE
day == DATE
at == O
4,008.05 == NUMBER
[ == O
24 == NUMBER
] == O
. == O
The == O
panic == O
also == O
affected == O
foreign == O
close the day at 4,008.05 [24]. The panic also  affected  foreign trade == O
. == O
Qatar == COUNTRY
temporarily == O
barred == O
travelers == O
from == O
Bangladesh == COUNTRY
. == O
The == O
trade.  Qatar  temporarily  barred travelers from Bangladesh. The Prime == TITLE
Minister == TITLE
of == O
India == COUNTRY
, == O
Narendra == PERSON
Modi == PERSON
, == O
has == O
canceled == O
his == O
trip == O
to == O
Prime Minister of India, Narendra Modi, has canceled his trip  to Bangladesh == COUNTRY
on == O
the == O
occasion == O
of == O
grand == O
inaugural == O
ceremony == O
of == O
Mujib == PERSON
Bangladesh  on  the occasion of grand inaugural ceremony of Mujib Year == DURATION
[ == O
25 == NUMBER
] == O
, == O
and == O
there == O
is == O
excessive == O
price == O
gouging == O
of == O
some == O
essen == O
‐ == O
Year [25], and there is excessive price gouging  of  some  essen‐ tials == O
such == O
as == O
infected == O
countries == O
and == O
Bangladesh == COUNTRY
with == O
a == O
percentage == O
tials such as infected countries and Bangladesh with a percentage share == O
of == O
global == O
cases == O
as == O
of == O
16 == DATE
March == DATE
2020 == DATE
. == O
( == O
Source == O
: == O
WHO == O
; == O
situa == O
‐ == O
share of global cases as of 16 March 2020. (Source:  WHO;  situa‐ tion == O
report == O
surgical == O
and == O
face == O
masks == O
, == O
sanitizers == O
, == O
electronics == O
and == O
tion  report surgical and face masks, sanitizers, electronics and electrical == O
materials == O
, == O
and == O
so == O
on == O
. == O
[ == O
26 == NUMBER
] == O
. == O
The == O
Government == O
on == O
14 == DATE
March == DATE
electrical materials, and so on. [26]. The Government on 14 March 2020 == DATE
declared == O
that == O
no == O
inbound == O
passengers == O
from == O
European == NATIONALITY
countries == O
2020  declared that no inbound passengers from European countries except == O
the == O
UK == COUNTRY
would == O
be == O
allowed == O
in == O
Bangladesh == COUNTRY
until == O
31 == DATE
March == DATE
2020 == DATE
. == O
except the UK would be allowed in Bangladesh until 31 March 2020. All == O
kinds == O
of == O
on == O
‐ == O
arrival == O
visas == O
have == O
been == O
suspended == O
for == O
new == O
2 == NUMBER
All  kinds  of  on‐arrival  visas  have  been suspended for new 2 weeks == DURATION
. == O
Besides == O
, == O
passengers == O
return == O
from == O
any == O
country == O
would == O
be == O
self == O
‐ == O
weeks. Besides, passengers return from any country would be self‐ quarantined == O
for == O
14 == DURATION
days == DURATION
[ == O
27 == NUMBER
] == O
. == O
Still == O
, == O
any == O
relaxation == O
on == O
monitoring == O
quarantined for 14 days [27]. Still, any relaxation on monitoring this == O
disease == CAUSE_OF_DEATH
would == O
be == O
very == O
costly == O
. == O
All == O
kinds == O
of == O
educational == O
in == O
‐ == O
this disease would be very costly. All kinds of  educational  in‐ stitutions == O
would == O
remain == O
close == O
until == O
31 == DATE
March == DATE
2020 == DATE
[ == O
27 == NUMBER
] == O
. == O
Moreover == O
, == O
stitutions would remain close until 31 March 2020 [27]. Moreover, all == O
sports == O
activities == O
to == O
be == O
postponed == O
until == O
31 == DATE
March == DATE
2020 == DATE
[ == O
27 == NUMBER
] == O
. == O
all sports activities to be postponed until 31 March  2020  [27]. Unlike == O
the == O
USA == COUNTRY
, == O
Spain == COUNTRY
, == O
Serbia == COUNTRY
, == O
France == COUNTRY
, == O
and == O
Lebanon == COUNTRY
, == O
Bangladesh == COUNTRY
Unlike  the  USA,  Spain, Serbia, France, and Lebanon, Bangladesh has == O
yet == O
to == O
declare == O
a == O
state == O
of == O
emergency == O
. == O
The == O
country == O
is == O
now == DATE
in == O
a == O
has yet to declare a state of emergency. The country is now in  a state == O
of == O
uncertainty == O
, == O
just == O
watching == O
the == O
global == O
initiatives == O
. == O
The == O
state  of uncertainty, just watching the global initiatives.  The Prime == TITLE
Minister == TITLE
( == O
PM == O
) == O
of == O
Bangladesh == COUNTRY
has == O
promptly == O
accepted == O
the == O
pres == O
‐ == O
Prime Minister (PM) of Bangladesh has promptly accepted the pres‐ ence == O
and == O
reality == O
of == O
COVID == O
‐ == O
19 == NUMBER
in == O
to == O
closely == O
monitor == O
the == O
situation == O
ence  and reality of COVID‐19 in to closely monitor the situation at == O
all == O
the == O
entry == O
points == O
of == O
Bangladesh == COUNTRY
and == O
to == O
improve == O
the == O
facili == O
‐ == O
at all the entry points of Bangladesh and to improve the  facili‐ ties == O
of == O
all == O
the == O
public == O
hospitals == O
by == O
ensuring == O
enough == O
quarantine == O
ties  of  all  the public hospitals by ensuring enough quarantine facilities == O
. == O
The == O
PM == O
also == O
canceled == O
all == O
the == O
prescheduled == O
meetings == O
, == O
facilities. The PM also canceled all the  prescheduled  meetings, processions == O
, == O
public == O
gatherings == O
, == O
and == O
foreign == O
trips == O
. == O
Epidemiology == O
processions,  public gatherings, and foreign trips.  Epidemiology of == O
COVID == O
‐ == O
19 == NUMBER
Environmental == O
factors == O
such == O
as == O
temperature == O
, == O
humidity == O
, == O
of COVID‐19 Environmental factors such as temperature,  humidity, and == O
wind == O
speed == O
have == O
a == O
significant == O
effect == O
on == O
the == O
survival == O
and == O
and  wind  speed  have  a  significant effect on the survival and transmission == O
of == O
human == O
coronaviruses == O
such == O
as == O
SARSCoV == O
and == O
MERS == O
‐ == O
CoV == O
transmission of human coronaviruses such as SARSCoV and  MERS‐CoV [ == O
28 == NUMBER
] == O
. == O
In == O
general == TITLE
, == O
the == O
survival == O
of == O
viral == O
SARS == O
‐ == O
CoV == O
could == O
survive == O
[28].  In  general,  the survival of viral SARS‐CoV could survive for == O
5 == DURATION
days == DURATION
on == O
a == O
smooth == O
surface == O
at == O
22C25C == O
and == O
relative == O
humidity == O
for 5 days on a smooth surface at 22C25C  and  relative  humidity 40 == PERCENT
% == PERCENT
50 == PERCENT
% == PERCENT
[ == O
28 == NUMBER
] == O
. == O
However == O
, == O
it == O
is == O
lost == O
its == O
activity == O
with == O
the == O
increase == O
40%50%  [28].  However, it is lost its activity with the increase of == O
temperature == O
and == O
relative == O
humidity == O
at == O
38C == O
and == O
95 == PERCENT
% == PERCENT
, == O
respective == O
‐ == O
of temperature and relative humidity at 38C and 95%,  respective‐ ly == O
. == O
The == O
possible == O
transmission == O
of == O
SARS == O
‐ == O
CoV == O
has == O
occurred == O
through == O
ly.  The  possible  transmission of SARS‐CoV has occurred through airborne == O
droplets == O
. == O
Furthermore == O
, == O
this == O
virus == O
could == O
survive == O
in == O
human == O
airborne droplets. Furthermore, this virus could survive in human feces == O
[ == O
30 == NUMBER
] == O
. == O
Another == O
human == O
coronavirus == O
MERS == O
‐ == O
CoV == O
could == O
remain == O
ac == O
‐ == O
feces  [30].  Another human coronavirus MERS‐CoV could remain ac‐ tive == O
for == O
an == O
extended == O
period == O
as == O
droplets == O
on == O
the == O
solid == O
surface == O
at == O
tive for an extended period as droplets on the solid  surface  at high == O
temperature == O
( == O
15C35C == O
) == O
and == O
low == O
humidity == O
( == O
< == O
20 == PERCENT
% == PERCENT
) == O
. == O
However == O
, == O
with == O
high  temperature (15C35C) and low humidity (<20%). However, with the == O
increase == O
of == O
relative == O
humidity == O
( == O
> == O
35 == PERCENT
% == PERCENT
) == O
and == O
temperatures == O
the  increase  of  relative  humidity  (>35%)  and   temperatures ( == O
5C15C == O
) == O
, == O
the == O
survivability == O
and == O
spread == O
of == O
MERS == O
‐ == O
CoV == O
would == O
be == O
re == O
‐ == O
(5C15C),  the  survivability  and spread of MERS‐CoV would be re‐ duced == O
[ == O
31 == NUMBER
] == O
. == O
Although == O
newly == O
emerged == O
novel == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
virus == O
has == O
duced [31].  Although newly emerged novel  SARS‐CoV‐2  virus  has similar == O
origin == O
with == O
SARS == O
‐ == O
CoV == O
and == O
MERS == O
‐ == O
CoV == O
, == O
the == O
role == O
of == O
tempera == O
‐ == O
similar  origin  with SARS‐CoV and MERS‐CoV, the role of tempera‐ ture == O
and == O
absolute == O
humidity == O
in == O
the == O
transmission == O
is == O
yet == O
to == O
be == O
ture and absolute humidity in  the  transmission  is  yet  to  be clearly == O
understood == O
. == O
The == O
contradictory == O
reports == O
have == O
scientists == O
in == O
clearly  understood. The contradictory reports have scientists in China == COUNTRY
[ == O
32 == NUMBER
] == O
reported == O
that == O
the == O
increased == O
temperature == O
and == O
humidity == O
China [32] reported that the increased temperature  and  humidity did == O
not == O
reduce == O
the == O
incidence == O
of == O
COVID == O
‐ == O
19 == NUMBER
[ == O
32 == NUMBER
] == O
. == O
However == O
, == O
according == O
did not reduce the incidence of COVID‐19 [32]. However, according to == O
Wang == PERSON
et == O
al. == O
[ == O
29 == NUMBER
] == O
, == O
the == O
increased == O
temperate == O
and == O
relative == O
humidi == O
‐ == O
to Wang et al. [29], the increased temperate and relative humidi‐ ty == O
significantly == O
reduced == O
the == O
transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
in == O
100 == NUMBER
ty  significantly  reduced  the  transmission  of COVID‐19 in 100 cities == O
of == O
China == COUNTRY
. == O
Similarly == O
, == O
another == O
group == O
reported == O
that == O
the == O
cities of China.  Similarly,  another  group  reported  that  the COVID == O
‐ == O
19 == NUMBER
COVID‐19 Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 virus == O
is == O
sensitive == O
to == O
high == O
temperatures == O
( == O
> == O
30C == NUMBER
) == O
[ == O
33 == NUMBER
] == O
. == O
Using == O
the == O
virus is sensitive to high temperatures (>30C)  [33].  Using  the current == DATE
statistics == O
available == O
in == O
situation == O
report == O
55 == NUMBER
at == O
the == O
WHO == O
current  statistics  available  in situation report 55 at the WHO website == O
[ == O
8 == NUMBER
] == O
, == O
the == O
cumulative == O
rate == O
of == O
confirmed == O
cases == O
and == O
deaths == O
of == O
website [8], the cumulative rate of confirmed cases and deaths of COVID == O
‐ == O
19 == NUMBER
is == O
1.4 == PERCENT
% == PERCENT
and == O
0.52 == PERCENT
% == PERCENT
, == O
respectively == O
, == O
in == O
tropical == O
or == O
subtrop == O
‐ == O
COVID‐19 is 1.4% and 0.52%, respectively, in tropical or subtrop‐ ical == O
countries == O
or == O
regions == O
, == O
but == O
it == O
is == O
98.59 == PERCENT
% == PERCENT
and == O
99.47 == PERCENT
% == PERCENT
, == O
respec == O
‐ == O
ical countries or regions, but it is 98.59% and  99.47%,  respec‐ tively == O
, == O
in == O
temperate == O
countries == O
or == O
subtropical == O
and == O
temperate == O
re == O
‐ == O
tively,  in  temperate countries or subtropical and temperate re‐ gions == O
/ == O
countries == O
. == O
Tropical == O
/ == O
subtropical == O
countries == O
or == O
regions == O
Tem == O
‐ == O
gions/countries.  Tropical/subtropical countries or regions  Tem‐ perate == O
countries == O
or == O
regions == O
Confirmed == O
cases == O
Confirmed == O
cases == O
Saudi == NATIONALITY
perate countries or regions Confirmed cases Confirmed cases Saudi Arabia == LOCATION
Sri == COUNTRY
Lanka == COUNTRY
United == COUNTRY
Kingdom == COUNTRY
United == COUNTRY
States == COUNTRY
of == O
Total == O
Confirmed == O
Arabia Sri Lanka United Kingdom United States of Total  Confirmed cases == O
Total == O
deaths == O
Percent == O
of == O
confirmed == O
cases == O
in == O
tropical == O
/ == O
sub == O
‐ == O
cases  Total  deaths Percent of confirmed cases in tropical/ sub‐ tropical == O
countries == O
/ == O
regions == O
Percent == O
of == O
confirmed == O
cases == O
in == O
temper == O
‐ == O
tropical countries/regions Percent of confirmed cases in  temper‐ ate == O
countries == O
/ == O
regions == O
Percent == O
of == O
death == O
in == O
tropical == O
/ == O
subtropical == O
ate  countries/ regions Percent of death in tropical/ subtropical countries == O
/ == O
regions == O
Percent == O
of == O
death == O
in == O
temperate == O
countries == O
/ == O
regions == O
countries/regions Percent of death in temperate countries/regions Up == O
to == O
16 == DATE
March == DATE
2020 == DATE
[ == O
8 == NUMBER
] == O
. == O
Up to 16 March 2020 [8]. Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
and == O
deaths == O
in == O
different == O
climatic == O
regions == O
transmission of COVID‐19 and deaths in different climatic regions are == O
caused == O
by == O
the == O
variation == O
of == O
temperature == O
and == O
relative == O
humidity == O
are  caused by the variation of temperature and relative humidity in == O
these == O
countries == O
or == O
regions == O
. == O
Although == O
the == O
mechanism == O
of == O
trans == O
‐ == O
in these countries or regions.  Although the mechanism of  trans‐ mission == O
of == O
COVID == O
‐ == O
19 == NUMBER
is == O
not == O
fully == O
understood == O
, == O
the == O
recent == O
studies == O
mission  of  COVID‐19 is not fully understood, the recent studies of == O
Huang == PERSON
et == O
al == O
. == O
[ == O
34 == NUMBER
] == O
and == O
Chan == PERSON
et == O
al. == O
[ == O
35 == NUMBER
] == O
have == O
reported == O
human == O
‐ == O
of Huang et al.  [34] and Chan et al. [35] have  reported  human‐ to == O
‐ == O
human == O
transmission == O
through == O
the == O
respiratory == O
droplets == O
and == O
sur == O
‐ == O
to‐human  transmission  through the respiratory droplets and sur‐ face == O
contact == O
. == O
The == O
droplets == O
are == O
generated == O
from == O
the == O
infected == O
person == O
face contact. The droplets are generated from the infected person through == O
his == O
coughs == O
or == O
sneezes == O
, == O
which == O
could == O
potentially == O
infect == O
through  his  coughs  or  sneezes, which could potentially infect others == O
remaining == O
in == O
close == O
contact == O
[ == O
36 == NUMBER
] == O
. == O
The == O
virus == O
within == O
the == O
others remaining in close contact  [36].  The  virus  within  the droplets == O
could == O
remain == O
viable == O
on == O
the == O
surface == O
of == O
an == O
object == O
for == O
a == O
droplets  could  remain  viable on the surface of an object for a few == DURATION
days == DURATION
; == O
thus == O
, == O
the == O
nearby == O
surroundings == O
of == O
an == O
infected == O
person == O
are == O
few days; thus, the nearby surroundings of an infected person are potential == O
sources == O
of == O
contamination == O
. == O
The == O
symptomatic == O
( == O
sickest == O
) == O
potential  sources  of  contamination.  The symptomatic (sickest) persons == O
are == O
thought == O
to == O
be == O
most == O
contagious == O
. == O
Moreover == O
, == O
recent == O
evi == O
‐ == O
persons are thought to be most contagious. Moreover, recent  evi‐ dence == O
suggests == O
that == O
a == O
person == O
without == O
symptoms == O
( == O
asymptomatic == O
) == O
dence  suggests  that  a  person  without symptoms (asymptomatic) could == O
potentially == O
spread == O
the == O
pathogen == O
during == O
the == O
incubation == O
peri == O
‐ == O
could potentially spread the pathogen during the incubation peri‐ od == O
[ == O
37 == NUMBER
] == O
. == O
Unlike == O
SARS == O
virus == O
, == O
the == O
risk == O
of == O
contamination == O
by == O
COVID19 == O
od [37].  Unlike SARS virus, the risk of contamination by COVID19 virus == O
through == O
feces == O
of == O
an == O
infected == O
person == O
is == O
low == O
[ == O
34 == NUMBER
] == O
. == O
Besides == O
, == O
virus through feces of an infected person is low [34].   Besides, there == O
is == O
no == O
evidence == O
of == O
airborne == O
dissemination == O
of == O
The == O
subtropical == O
there is no evidence of airborne dissemination of The subtropical monsoon == O
climate == O
in == O
Bangladesh == COUNTRY
is == O
characterized == O
by == O
heavy == O
summer == DATE
monsoon climate in Bangladesh is characterized  by  heavy  summer rainfall == O
and == O
high == O
summer == DATE
temperature == O
with == O
often == O
excessive == O
humidi == O
‐ == O
rainfall and high summer temperature with often excessive humidi‐ ty == O
. == O
The == O
range == O
of == O
ambient == O
temperature == O
in == O
the == O
summer == DATE
is == O
36C40C == O
, == O
and == O
ty. The range of ambient temperature in the summer is 36C40C, and winter == DATE
temperature == O
is == O
8C15C == O
[ == O
38 == NUMBER
] == O
. == O
If == O
the == O
studies == O
of == O
Wang == PERSON
et == O
al == O
. == O
winter  temperature  is 8C15C [38]. If the studies of Wang et al. [ == O
29,33 == NUMBER
] == O
are == O
true == O
and == O
if == O
the == O
trend == O
of == O
disease == CAUSE_OF_DEATH
occurrence == O
particu == O
‐ == O
[29,33] are true and if the trend of disease occurrence  particu‐ larly == O
in == O
the == O
summer == DATE
season == O
. == O
Although == O
the == O
mechanism == O
of == O
high == O
tem == O
‐ == O
larly  in  the summer season. Although the mechanism of high tem‐ perature == O
and == O
high == O
humidity == O
reduces == O
the == O
transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
perature and high humidity reduces the transmission  of  COVID‐19 is == O
not == O
known == O
yet == O
, == O
in == O
the == O
case == O
of == O
temperatures == O
, == O
and == O
respiratory == O
is  not  known  yet, in the case of temperatures, and respiratory droplets == O
remain == O
airborne == O
longer == O
in == O
dry == O
air == O
[ == O
39,40 == NUMBER
] == O
. == O
Second == ORDINAL
, == O
cold == O
droplets remain airborne longer in dry air [39,40]. Second,  cold and == O
dry == O
weather == O
impairs == O
mucociliary == O
clearance == O
, == O
innate == O
antiviral == O
and  dry  weather impairs mucociliary clearance, innate antiviral immunity == O
, == O
and == O
tissue == O
repair == O
and == O
makes == O
them == O
more == O
susceptible == O
to == O
immunity, and tissue repair and makes them  more  susceptible  to the == O
virus == O
[ == O
41,42 == NUMBER
] == O
. == O
These == O
mechanisms == O
are == O
also == O
likely == O
to == O
applicable == O
the virus [41,42]. These mechanisms are also likely to applicable for == O
the == O
COVID == O
‐ == O
19 == NUMBER
transmission == O
. == O
Pathogenesis == O
of == O
COVID == O
‐ == O
19 == NUMBER
The == O
for the COVID‐19  transmission.   Pathogenesis  of  COVID‐19  The clinical == O
signs == O
and == O
symptoms == O
are == O
almost == O
similar == O
to == O
that == O
of == O
SARS == O
clinical  signs  and  symptoms are almost similar to that of SARS and == O
MERS == O
infections == CAUSE_OF_DEATH
[ == O
43 == NUMBER
] == O
. == O
Hence == O
, == O
although == O
the == O
pathogenesis == O
of == O
and MERS infections [43]. Hence,  although  the  pathogenesis  of COVID == O
‐ == O
19 == NUMBER
is == O
poorly == O
understood == O
, == O
the == O
similar == O
mechanisms == O
of == O
SARS == O
and == O
COVID‐19 is poorly understood, the similar mechanisms of SARS and MERS == O
still == O
can == O
give == O
us == O
a == O
lot == O
of == O
information == O
on == O
the == O
pathogenesis == O
MERS still can give us a lot of information on  the  pathogenesis of == O
COVID == O
‐ == O
19 == NUMBER
. == O
The == O
lungs == O
are == O
made == O
up == O
of == O
a == O
mass == O
of == O
alveoli == O
. == O
The == O
of  COVID‐19.   The  lungs  are made up of a mass of alveoli. The alveoli == O
are == O
responsible == O
for == O
gaseous == O
exchange == O
, == O
providing == O
oxygen == O
to == O
alveoli are responsible for gaseous exchange, providing oxygen to blood == O
flowing == O
through == O
capillaries == O
in == O
the == O
alveolar == O
membrane == O
. == O
The == O
blood  flowing  through capillaries in the alveolar membrane. The alveolar == O
walls == O
are == O
composed == O
of == O
type == O
I == NUMBER
and == O
type == O
II == NUMBER
pneumocytes == O
, == O
alveolar walls are composed of type I and  type  II  pneumocytes, along == O
with == O
alveolar == O
macrophages == O
( == O
Fig. == O
3 == NUMBER
) == O
[ == O
44 == NUMBER
] == O
. == O
Type == O
I == NUMBER
pneumocytes == O
along with alveolar macrophages (Fig. 3) [44]. Type I pneumocytes are == O
responsible == O
for == O
gaseous == O
exchange == O
with == O
blood == O
in == O
the == O
capillar == O
‐ == O
are responsible for gaseous exchange with blood in the  capillar‐ ies == O
of == O
the == O
lungs == O
. == O
Type == O
II == NUMBER
pneumocytes == O
are == O
the == O
progenitors == O
of == O
type == O
ies of the lungs. Type II pneumocytes are the progenitors of type I == O
pneumocytes == O
and == O
are == O
also == O
responsible == O
for == O
producing == O
surfactant == O
I pneumocytes and are also responsible for  producing  surfactant [ == O
45 == NUMBER
] == O
. == O
SARS == O
‐ == O
CoV == O
infection == CAUSE_OF_DEATH
causes == O
desquamation == O
of == O
pneumocytes == O
by == O
[45].   SARS‐CoV  infection causes desquamation of pneumocytes by releasing == O
inflammatory == O
cytokine == O
in == O
humans == O
and == O
rats == O
and == O
alveolar == O
releasing inflammatory cytokine in humans and rats  and  alveolar swelling == O
, == O
edema == O
, == O
and == O
hemorrhage == CAUSE_OF_DEATH
in == O
the == O
lungs == O
( == O
Fig. == O
3 == NUMBER
) == O
[ == O
46 == NUMBER
] == O
. == O
The == O
swelling,  edema,  and hemorrhage in the lungs (Fig. 3) [46]. The virus == O
also == O
destroys == O
alveolar == O
macrophages == O
that == O
play == O
an == O
essential == O
virus also destroys alveolar macrophages that play  an  essential role == O
in == O
local == O
immune == O
response == O
[ == O
47 == NUMBER
] == O
. == O
In == O
critical == O
illness == CAUSE_OF_DEATH
, == O
uncon == O
‐ == O
role  in local immune response [47].  In critical illness, uncon‐ trolled == O
inflammation == O
, == O
fluid == O
accumulation == O
, == O
and == O
developing == O
fibrosis == O
trolled inflammation, fluid accumulation, and developing fibrosis severely == O
compromise == O
gas == O
exchange == O
and == O
lead == O
to == O
respiratory == CAUSE_OF_DEATH
failure == CAUSE_OF_DEATH
severely  compromise gas exchange and lead to respiratory failure [ == O
42 == NUMBER
] == O
. == O
Symptoms == O
of == O
COVID == O
‐ == O
19 == NUMBER
The == O
symptoms == O
of == O
COVID == O
‐ == O
19 == NUMBER
are == O
either == O
[42].  Symptoms of COVID‐19 The symptoms of COVID‐19  are  either asymptomatic == O
( == O
no == O
signs == O
) == O
or == O
symptomatic == O
( == O
non == O
‐ == O
, == O
mild == O
‐ == O
, == O
or == O
severe == O
asymptomatic  (no  signs)  or symptomatic (non‐, mild‐, or severe pneumonia == CAUSE_OF_DEATH
) == O
[ == O
48 == NUMBER
] == O
. == O
The == O
range == O
of == O
mild == O
disease == CAUSE_OF_DEATH
( == O
i.e. == O
, == O
nonpneumonia == O
or == O
pneumonia) [48]. The range of mild disease (i.e., nonpneumonia or mild == O
pneumonia == CAUSE_OF_DEATH
) == O
is == O
about == O
80 == PERCENT
% == PERCENT
of == O
cases == O
( == O
mostly == O
curable == O
) == O
, == O
mildto == O
‐ == O
mild  pneumonia)  is about 80% of cases (mostly curable), mildto‐ severe == O
pneumonia == CAUSE_OF_DEATH
is == O
about == O
14 == PERCENT
% == PERCENT
, == O
and == O
critical == O
illness == CAUSE_OF_DEATH
is == O
about == O
6 == PERCENT
% == PERCENT
severe pneumonia is about 14%, and critical illness is  about  6% of == O
cases == O
[ == O
22 == NUMBER
] == O
. == O
The == O
critical == O
illnesses == O
lead == O
to == O
severe == O
consequences == O
of cases [22]. The critical illnesses lead to severe consequences such == O
as == O
a == O
death == O
in == O
the == O
case == O
of == O
the == O
elderly == O
or == O
other == O
people == O
who == O
such as a death in the case of the elderly or  other  people  who have == O
severe == O
chronic == O
medical == O
conditions == O
such == O
as == O
heart == CAUSE_OF_DEATH
disease == CAUSE_OF_DEATH
, == O
di == O
‐ == O
have severe chronic medical conditions such as heart disease, di‐ abetes == O
, == O
and == O
lung == O
diseases == CAUSE_OF_DEATH
[ == O
15 == NUMBER
] == O
. == O
Other == O
common == O
signs == O
of == O
COVID == O
‐ == O
19 == NUMBER
abetes, and lung diseases [15].  Other common signs  of  COVID‐19 infection == CAUSE_OF_DEATH
are == O
respiratory == O
symptoms == O
, == O
fever == CAUSE_OF_DEATH
, == O
coughing == O
, == O
sneezing == O
, == O
infection  are  respiratory  symptoms, fever, coughing, sneezing, shortness == O
of == O
breath == O
, == O
Diagnosis == O
of == O
COVID == O
‐ == O
19 == NUMBER
infection == CAUSE_OF_DEATH
As == O
there == O
are == O
shortness of breath, Diagnosis of COVID‐19 infection As there are no == O
specific == O
therapeutic == O
drugs == CRIMINAL_CHARGE
or == O
vaccines == O
available == O
for == O
novel == O
no  specific  therapeutic  drugs  or vaccines available for novel COVID == O
‐ == O
19 == NUMBER
; == O
therefore == O
, == O
it == O
is == O
essential == O
to == O
detect == O
the == O
disease == CAUSE_OF_DEATH
at == O
an == O
COVID‐19; therefore, it is essential to detect the disease at  an early == O
stage == O
so == O
that == O
immediate == O
isolation == O
of == O
the == O
patient == O
could == O
be == O
early  stage  so that immediate isolation of the patient could be undertaken == O
. == O
Thus == O
, == O
the == O
radiological == O
examination == O
is == O
used == O
for == O
the == O
undertaken. Thus, the radiological examination is  used  for  the early == O
detection == O
of == O
COVID == O
‐ == O
19 == NUMBER
[ == O
49 == NUMBER
] == O
. == O
Thin == O
‐ == O
slice == O
chest == O
CT == STATE_OR_PROVINCE
functions == O
early  detection  of COVID‐19 [49]. Thin‐slice chest CT functions are == O
more == O
effectively == O
detecting == O
pneumonia == CAUSE_OF_DEATH
caused == O
by == O
COVID == O
‐ == O
19 == NUMBER
at == O
a == O
are more effectively detecting pneumonia caused by COVID‐19 at  a very == O
early == O
stage == O
[ == O
50 == NUMBER
] == O
. == O
The == O
sensitivity == O
of == O
CT == STATE_OR_PROVINCE
for == O
COVID == O
‐ == O
19 == NUMBER
infec == O
‐ == O
very  early stage [50]. The sensitivity of CT for COVID‐19 infec‐ tion == O
was == O
98 == PERCENT
% == PERCENT
, == O
but == O
it == O
was == O
much == O
higher == O
than == O
the == O
sensitivity == O
( == O
71 == PERCENT
% == PERCENT
; == O
p == O
tion was 98%, but it was much higher than the sensitivity (71%; p < == O
0.001 == NUMBER
) == O
of == O
RT == O
‐ == O
PCR == O
[ == O
49,51 == NUMBER
] == O
. == O
Although == O
nucleic == O
acid == O
‐ == O
based == O
( == O
3 == PERCENT
% == PERCENT
) == O
pa == O
‐ == O
<  0.001) of RT‐PCR [49,51]. Although nucleic acid‐based (3%) pa‐ tients == O
, == O
who == O
had == O
negative == O
RT == O
‐ == O
qPCR == O
for == O
COVID == O
‐ == O
19 == NUMBER
at == O
the == O
initial == O
tients, who had negative RT‐qPCR  for  COVID‐19  at  the  initial stage == O
of == O
COVID == O
‐ == O
19 == NUMBER
but == O
conduction == O
of == O
chest == O
CT == STATE_OR_PROVINCE
, == O
confirmed == O
viral == O
stage  of  COVID‐19  but  conduction of chest CT, confirmed viral pneumonia == CAUSE_OF_DEATH
at == O
the == O
early == O
stage == O
. == O
The == O
collection == O
of == O
samples == O
for == O
the == O
pneumonia at the early stage.  The collection of samples for  the detection == O
of == O
the == O
virus == O
is == O
a == O
big == O
challenge == O
for == O
the == O
health == O
workers == O
. == O
detection of the virus is a big challenge for the health workers. The == O
recommended == O
specimens == O
for == O
COVID == O
‐ == O
19 == NUMBER
diagnosis == O
are == O
nasopharyn == O
‐ == O
The recommended specimens for COVID‐19 diagnosis are  nasopharyn‐ geal == O
and == O
oropharyngeal == O
swabs == O
; == O
however == O
, == O
the == O
collection == O
of == O
these == O
geal  and  oropharyngeal  swabs; however, the collection of these samples == O
requires == O
close == O
contact == O
with == O
the == O
patients == O
, == O
which == O
poses == O
a == O
samples requires close contact with the patients, which  poses  a risk == O
of == O
transmission == O
of == O
the == O
viruses == O
to == O
the == O
healthcare == O
personnel == O
. == O
risk  of transmission of the viruses to the healthcare personnel. Therefore == O
, == O
saliva == O
specimens == O
are == O
suggested == O
because == O
patients == O
could == O
Therefore, saliva specimens are suggested because patients  could easily == O
spit == O
their == O
saliva == O
into == O
a == O
sterile == O
bottle == O
in == O
a == O
noninvasive == O
easily  spit  their saliva into a sterile bottle in a noninvasive way == O
[ == O
53 == NUMBER
] == O
. == O
Meanwhile == O
, == O
real == O
‐ == O
time == O
RT == O
‐ == O
PCR == O
using == O
blood == O
samples == O
gave == O
a == O
way [53]. Meanwhile, real‐time RT‐PCR using blood samples gave  a very == O
low == O
percentage == O
very low percentage Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 and == O
resident == O
alveolar == O
macrophages == O
and == O
pulmonary == O
surfactant == O
exist == O
and resident alveolar macrophages and pulmonary surfactant  exist in == O
the == O
airspace == O
( == O
A == O
) == O
. == O
In == O
the == O
acute == O
phase == O
of == O
SARS == O
‐ == O
CoV == O
infection == CAUSE_OF_DEATH
in  the  airspace  (A).  In the acute phase of SARS‐CoV infection ( == O
B == O
) == O
, == O
type == O
I == NUMBER
and == O
type == O
II == NUMBER
pneumocytes == O
are == O
infected == O
and == O
secrete == O
in == O
‐ == O
(B), type I and type II pneumocytes are infected and secrete  in‐ flammatory == O
cytokines == O
, == O
whereas == O
surfactant == O
levels == O
decrease == O
. == O
In == O
se == O
‐ == O
flammatory  cytokines, whereas surfactant levels decrease. In se‐ vere == O
illness == CAUSE_OF_DEATH
, == O
inflammation == O
, == O
fluid == O
accumulation == O
, == O
and == O
developing == O
vere illness, inflammation, fluid  accumulation,  and  developing fibrosis == O
severely == O
damage == O
alveoli == O
and == O
lead == O
to == O
respiratory == CAUSE_OF_DEATH
failure == CAUSE_OF_DEATH
fibrosis  severely damage alveoli and lead to respiratory failure ( == O
C == O
) == O
. == O
Clinical == O
signs == O
and == O
Zoonotic == MISC
transmission == O
Incubation == O
period == O
(C).  Clinical signs and Zoonotic transmission Incubation  period Bats == O
harbor == O
the == O
three == NUMBER
coronaviruses == O
as == O
a == O
reservoir == O
host == TITLE
. == O
It == O
is == O
Bats  harbor  the three coronaviruses as a reservoir host.  It is still == O
unclear == O
whether == O
the == O
COVID == O
‐ == O
19 == NUMBER
transmitted == O
from == O
bats == O
to == O
hu == O
‐ == O
still unclear whether the COVID‐19 transmitted from bats  to  hu‐ mans == O
[ == O
10 == NUMBER
] == O
. == O
Then == O
, == O
humanto == O
‐ == O
human == O
transmission == O
through == O
droplets == O
, == O
mans  [10].  Then,  humanto‐human  transmission through droplets, personal == O
( == O
handshaking == O
) == O
, == O
and == O
contaminated == O
surface == O
contact == O
[ == O
34,35 == NUMBER
] == O
. == O
personal (handshaking), and contaminated surface contact [34,35]. It == O
seems == O
to == O
be == O
more == O
transmissible == O
than == O
SARS == O
and == O
214 == DURATION
days == DURATION
[ == O
10,55 == NUMBER
] == O
It  seems to be more transmissible than SARS and 214 days [10,55] Mostly == O
respiratory == O
symptoms == O
, == O
such == O
as == O
fever == CAUSE_OF_DEATH
, == O
dry == O
cough == O
, == O
shortness == O
Mostly respiratory symptoms, such as fever, dry cough,  shortness of == O
breath == O
, == O
and == O
in == O
the == O
most == O
severe == O
cases == O
, == O
have == O
pneumonia == CAUSE_OF_DEATH
[ == O
10 == NUMBER
] == O
Pri == O
‐ == O
of breath, and in the most severe cases, have pneumonia [10] Pri‐ marily == O
transmitted == O
from == O
bats == O
to == O
snakes == O
, == O
civet == O
cats == O
, == O
and == O
finally == O
marily transmitted from bats to snakes, civet cats,  and  finally to == O
human == O
[ == O
10 == NUMBER
] == O
. == O
Then == O
, == O
similar == O
transmission == O
to == O
COVID == O
‐ == O
19 == NUMBER
, == O
including == O
to  human [10]. Then, similar transmission to COVID‐19, including fecal == O
[ == O
34,60 == NUMBER
] == O
. == O
210 == DURATION
days == DURATION
, == O
up == DURATION
to == DURATION
14 == DURATION
days == DURATION
[ == O
10 == NUMBER
] == O
Primarily == O
transmit == O
‐ == O
fecal [34,60].  210 days, up to 14 days [10] Primarily  transmit‐ ted == O
from == O
bats == O
to == O
camels == O
and == O
finally == O
to == O
human == O
[ == O
10 == NUMBER
] == O
and == O
then == O
human == O
ted  from bats to camels and finally to human [10] and then human to == O
human == O
transmission == O
via == O
direct == O
respiratory == O
secretion == O
contact == O
to human transmission via direct  respiratory  secretion  contact [ == O
34 == NUMBER
] == O
and == O
also == O
fecal == O
‐ == O
oral == O
transmission == O
[ == O
60 == NUMBER
] == O
. == O
days == DURATION
[ == O
10 == NUMBER
] == O
Clinical == O
[34]  and  also fecal‐oral transmission [60].  days [10] Clinical diagnosis == O
based == O
on == O
symptoms == O
, == O
history == O
and == O
chest == O
imaging == O
, == O
and == O
diag == O
‐ == O
diagnosis based on symptoms, history and chest imaging, and diag‐ nosis == O
by == O
nucleic == O
acid == O
test == O
, == O
such == O
as == O
RT == O
‐ == O
qPCR == O
, == O
deep == O
sequencing == O
, == O
and == O
nosis by nucleic acid test, such as RT‐qPCR, deep sequencing, and ELISA == ORGANIZATION
[ == O
34,56 == NUMBER
] == O
. == O
No == O
antiviral == O
drug == O
yet == O
[ == O
57,58 == NUMBER
] == O
. == O
Oxygen == O
and == O
fluid == O
ELISA [34,56].  No antiviral drug yet [57,58]. Oxygen  and  fluid therapy == O
and == O
antibiotics == O
with == O
oseltamivir == O
[ == O
34,57,58 == NUMBER
] == O
. == O
In == O
severe == O
therapy  and  antibiotics with oseltamivir [34,57,58].  In severe illness == CAUSE_OF_DEATH
, == O
corticosteroids == O
are == O
used == O
to == O
reduce == O
lung == O
inflammation == O
illness, corticosteroids are used  to  reduce  lung  inflammation [ == O
59 == NUMBER
] == O
. == O
Besides == O
respiratory == O
Similar == O
to == O
COVID == O
‐ == O
19 == NUMBER
symptoms == O
[ == O
10 == NUMBER
] == O
, == O
the == O
[59].  Besides respiratory Similar to COVID‐19 symptoms [10], the virus == O
is == O
known == O
to == O
cause == O
enteric == O
symptom == O
, == O
such == O
as == O
diarrhea == O
and == O
ab == O
‐ == O
virus is known to cause enteric symptom, such as diarrhea and ab‐ dominal == O
pain == O
, == O
and == O
finally == O
focal == O
necrosis == O
and == O
nephritis == CAUSE_OF_DEATH
in == O
the == O
dominal  pain,  and  finally  focal necrosis and nephritis in the kidney == O
[ == O
60 == NUMBER
] == O
. == O
Similar == O
to == O
COVID == O
‐ == O
19 == NUMBER
Severe == O
acute == O
respiratory == O
dis == O
‐ == O
kidney [60].  Similar to COVID‐19 Severe acute  respiratory  dis‐ tress == O
, == O
severe == O
pneumonia == CAUSE_OF_DEATH
, == O
enteric == O
symptoms == O
, == O
and == O
kidney == CAUSE_OF_DEATH
failure == CAUSE_OF_DEATH
tress,  severe  pneumonia,  enteric  symptoms, and kidney failure [ == O
60,61 == NUMBER
] == O
. == O
Similar == O
to == O
COVID == O
‐ == O
19 == NUMBER
Similar == O
to == O
COVID == O
‐ == O
19 == NUMBER
[60,61].  Similar to COVID‐19 Similar to COVID‐19 Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam et al./ J. Adv. Vet. Anim. Res., 7(2):  198208,  June  2020 ( == O
1 == PERCENT
% == PERCENT
) == O
of == O
the == O
positive == O
results == O
, == O
and == O
urine == O
samples == O
did == O
not == O
give == O
pos == O
‐ == O
(1%) of the positive results, and urine samples did not give pos‐ itive == O
results == O
[ == O
54 == NUMBER
] == O
. == O
which == O
provides == O
the == O
diagnostic == O
facilities == O
of == O
itive results [54].  which provides the diagnostic facilities  of COVID == O
‐ == O
19 == NUMBER
. == O
The == O
detection == O
of == O
COVID == O
‐ == O
19 == NUMBER
is == O
a == O
real == O
‐ == O
time == O
RT == O
‐ == O
PCR == O
‐ == O
based == O
COVID‐19.  The  detection of COVID‐19 is a real‐time RT‐PCR‐based assay == O
that == O
requires == O
skilled == O
human == O
resources == O
and == O
sophisticated == O
assay that requires skilled  human  resources  and  sophisticated laboratory == O
facilities == O
. == O
To == O
avoid == O
false == O
results == O
and == O
risks == O
of == O
bio == O
‐ == O
laboratory  facilities.  To avoid false results and risks of bio‐ logical == O
hazards == O
, == O
the == O
Government == O
is == O
not == O
allowing == O
any == O
other == O
private == O
logical hazards, the Government is not allowing any other private organizations == O
except == O
IEDCR == O
to == O
perform == O
this == O
[ == O
27 == NUMBER
] == O
. == O
The == O
rapid == O
test == O
organizations  except IEDCR to perform this [27].  The rapid test kits == O
are == O
although == O
available == O
in == O
Bangladesh == COUNTRY
, == O
but == O
the == O
WHO == ORGANIZATION
does == O
not == O
kits are although available in Bangladesh, but the WHO  does  not approve == O
these == O
kits == O
. == O
Prevention == O
and == O
control == O
of == O
COVID == O
‐ == O
19 == NUMBER
It == O
is == O
approve  these  kits.   Prevention  and control of COVID‐19 It is popularly == O
said == O
that == O
prevention == O
is == O
better == O
than == O
cure == O
. == O
Prevention == O
popularly said that prevention is better than  cure.   Prevention of == O
COVID == O
‐ == O
19 == NUMBER
should == O
be == O
the == O
prime == O
strategy == O
to == O
restrict == O
this == O
deadly == O
of  COVID‐19 should be the prime strategy to restrict this deadly disease == CAUSE_OF_DEATH
from == O
a == O
further == O
outbreak == O
in == O
Bangladesh == COUNTRY
. == O
The == O
WHO == ORGANIZATION
suggested == O
disease from a further outbreak in Bangladesh. The WHO  suggested that == O
the == O
transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
should == O
be == O
prevented == O
by == O
reducing == O
that the transmission of COVID‐19 should be prevented by reducing the == O
secondary == O
infections == CAUSE_OF_DEATH
among == O
close == O
contact == O
with == O
persons == O
who == O
the secondary infections among close  contact  with  persons  who suffer == O
from == O
acute == O
respiratory == CAUSE_OF_DEATH
infections == CAUSE_OF_DEATH
. == O
Besides == O
, == O
the == O
hands == O
suffer  from  acute  respiratory  infections.  Besides, the hands should == O
be == O
frequently == O
washed == O
after == O
direct == O
contact == O
with == O
a == O
sick == O
per == O
‐ == O
should be frequently washed after direct contact with a sick per‐ son == O
; == O
furthermore == O
, == O
the == O
unprotected == O
contact == O
with == O
wild == O
animals == O
son;  furthermore,  the  unprotected  contact  with  wild animals should == O
be == O
avoided == O
. == O
Moreover == O
, == O
the == O
COVID == O
‐ == O
19infected == O
person == O
should == O
should be avoided. Moreover, the COVID‐19infected  person  should maintain == O
a == O
good == O
practice == O
of == O
cough == O
etiquettes == O
such == O
as == O
by == O
covering == O
maintain  a good practice of cough etiquettes such as by covering coughs == O
and == O
sneezes == O
with == O
disposable == O
tissues == O
or == O
clean == O
clothes == O
, == O
by == O
coughs and sneezes with disposable tissues or clean  clothes,  by washing == O
hands == O
, == O
and == O
by == O
maintaining == O
distance == O
with == O
noninfected == O
per == O
‐ == O
washing  hands, and by maintaining distance with noninfected per‐ sons == O
[ == O
15 == NUMBER
] == O
. == O
In == O
addition == O
to == O
these == O
preventive == O
measures == O
, == O
the == O
Govern == O
‐ == O
sons [15]. In addition to these preventive measures, the  Govern‐ ment == O
of == O
Bangladesh == COUNTRY
should == O
be == O
undertaken == O
stern == O
actions == O
against == O
the == O
ment of Bangladesh should be undertaken stern actions against the passengers == O
, == O
such == O
as == O
strictly == O
measuring == O
their == O
body == O
temperature == O
or == O
passengers, such as strictly measuring their body temperature  or keep == O
them == O
in == O
an == O
isolation == O
condition == O
for == O
14 == DURATION
days == DURATION
at == O
the == O
land == O
, == O
sea == O
, == O
keep them in an isolation condition for 14 days at the land, sea, and == O
airports == O
after == O
arrival == O
from == O
COVID == O
‐ == O
19infected == O
countries == O
. == O
Ef == O
‐ == O
and airports after arrival from COVID‐19infected countries.   Ef‐ fective == O
vaccines == O
are == O
essential == O
to == O
control == O
the == O
coronavirus == O
out == O
‐ == O
fective  vaccines  are  essential to control the coronavirus out‐ breaks == O
. == O
There == O
are == O
several == O
vaccination == O
strategies == O
used == O
against == O
breaks. There are several  vaccination  strategies  used  against SARS == O
‐ == O
CoV == O
, == O
and == O
MERS == O
‐ == O
CoV == O
tested == O
in == O
animals == O
, == O
including == O
a == O
live == O
‐ == O
atten == O
‐ == O
SARS‐CoV, and MERS‐CoV tested in animals, including a live‐atten‐ uated == O
virus == O
, == O
inactivated == O
virus == O
, == O
subunit == O
vaccines == O
, == O
recombinant == O
uated virus, inactivated  virus,  subunit  vaccines,  recombinant DNA == O
, == O
and == O
protein == O
vaccines == O
[ == O
62 == NUMBER
] == O
. == O
These == O
studies == O
are == O
still == O
underway == O
DNA, and protein vaccines [62].  These studies are still underway to == O
develop == O
vaccines == O
for == O
Unlike == O
SARS == O
‐ == O
CoV == O
and == O
MERS == O
‐ == O
CoV == O
, == O
no == O
proven == O
to develop vaccines for Unlike SARS‐CoV and MERS‐CoV,  no  proven vaccines == O
so == O
far == O
discovered == O
against == O
COVID == O
‐ == O
19 == NUMBER
. == O
However == O
, == O
the == O
first == ORDINAL
vaccines  so  far discovered against COVID‐19. However, the first trial == O
of == O
evaluating == O
a == O
vaccine == O
against == O
COVID == O
‐ == O
19 == NUMBER
has == O
begun == O
on == O
15 == NUMBER
trial of evaluating a vaccine against COVID‐19 has  begun  on  15 March == DATE
2020 == DATE
at == O
kaiser == O
permanente == O
washington == STATE_OR_PROVINCE
health == O
promising == O
tar == O
‐ == O
March  2020 at kaiser permanente washington health promising tar‐ gets == O
for == O
COVID == O
‐ == O
19 == NUMBER
, == O
but == O
more == O
clinical == O
trials == O
still == O
should == O
be == O
need == O
‐ == O
gets for COVID‐19, but more clinical trials still should be need‐ ed == O
. == O
Management == O
of == O
COVID == O
‐ == O
19 == NUMBER
contamination == O
Evidence == O
suggests == O
that == O
ed.   Management of COVID‐19 contamination Evidence suggests that the == O
virus == O
is == O
contaminated == O
from == O
human == O
to == O
human == O
very == O
rapidly == O
the virus is  contaminated  from  human  to  human  very  rapidly [ == O
35,64 == NUMBER
] == O
. == O
Although == O
complete == O
elimination == O
of == O
COVID == O
‐ == O
19 == NUMBER
outbreak == O
seems == O
[35,64]. Although complete elimination of COVID‐19 outbreak seems impossible == O
, == O
several == O
key == O
measures == O
could == O
reduce == O
the == O
possible == O
trans == O
‐ == O
impossible, several key measures could reduce the possible trans‐ mission == O
of == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
by == O
avoiding == O
the == O
contact == O
opportunities == O
of == O
mission  of  SARS‐CoV‐2  by avoiding the contact opportunities of outbreak == O
, == O
traveling == O
and == O
trade == O
restrictions == O
, == O
entry == O
screening == O
of == O
outbreak, traveling and trade restrictions,  entry  screening  of the == O
travelers == O
during == O
outbreak == O
period == O
, == O
isolation == O
of == O
infected == O
cas == O
‐ == O
the  travelers during outbreak period, isolation of infected cas‐ es == O
, == O
and == O
maintaining == O
the == O
physical == O
distance == O
within == O
the == O
workspace == O
. == O
es, and maintaining the physical distance within  the  workspace. In == O
this == O
backdrop == O
, == O
flexible == O
working == O
schedules == O
/ == O
shifts == O
for == O
employ == O
‐ == O
In  this  backdrop, flexible working schedules/shifts for employ‐ ees == O
, == O
the == O
opportunity == O
of == O
distance == O
working == O
/ == O
teleworking == O
, == O
increased == O
ees, the opportunity of distance  working/teleworking,  increased use == O
of == O
email == O
and == O
teleconferences == O
to == O
reduce == O
close == O
contacts == O
, == O
re == O
‐ == O
use  of  email  and teleconferences to reduce close contacts, re‐ duced == O
contact == O
between == O
employees == O
and == O
customers == O
, == O
reduced == O
contact == O
duced contact between employees and  customers,  reduced  contact between == O
employees == O
, == O
promoting == O
the == O
use == O
of == O
other == O
personal == O
protective == O
between employees, promoting the use of other personal protective countermeasures == O
, == O
and == O
avoiding == O
mass == O
gathering == O
, == O
such == O
as == O
sport == O
countermeasures, and  avoiding  mass  gathering,  such  as  sport events == O
, == O
concerts == O
, == O
religious == O
events == O
, == O
conferences == O
, == O
and == O
so == O
on == O
are == O
events,  concerts,  religious  events, conferences, and so on are advised == O
. == O
According == O
to == O
the == O
WHO == ORGANIZATION
, == O
the == O
practice == O
of == O
good == O
personal == O
hy == O
‐ == O
advised.  According to the WHO, the practice of good personal hy‐ giene == O
is == O
essential == O
[ == O
8,66 == NUMBER
] == O
. == O
Regularly == O
washing == O
hands == O
with == O
soaps == O
and == O
giene is essential [8,66]. Regularly washing hands with soaps and water == O
and == O
avoid == O
touching == O
the == O
face == O
with == O
the == O
hands == O
are == O
some == O
ways == O
to == O
water and avoid touching the face with the hands are some ways to ensure == O
personal == O
hygiene == O
. == O
Wearing == O
a == O
mask == O
is == O
not == O
essential == O
until == O
a == O
ensure  personal hygiene. Wearing a mask is not essential until a person == O
is == O
detected == O
with == O
SARSCoV == O
‐ == O
2 == NUMBER
to == O
protect == O
spreading == O
the == O
virus == O
person is detected with SARSCoV‐2 to protect spreading the  virus to == O
the == O
public == O
[ == O
67 == NUMBER
] == O
. == O
The == O
infected == O
person == O
should == O
take == O
rest == O
at == O
home == O
to  the public [67]. The infected person should take rest at home or == O
admit == O
to == O
the == O
hospital == O
for == O
complete == O
isolation == O
for == O
14 == DURATION
days == DURATION
. == O
In == O
or admit to the hospital for complete isolation for 14  days.  In case == O
of == O
emergency == O
, == O
the == O
infected == O
person == O
should == O
wear == O
a == O
surgical == O
case  of  emergency,  the  infected person should wear a surgical mask == O
to == O
protect == O
others == O
. == O
Potential == O
treatments == O
against == O
COVID == O
‐ == O
19 == NUMBER
As == O
mask to protect others.  Potential treatments against COVID‐19 As we == O
know == O
, == O
no == O
effective == O
treatments == O
are == O
available == O
for == O
viral == O
diseases == CAUSE_OF_DEATH
we know, no effective treatments are available for viral diseases [ == O
57,58 == NUMBER
] == O
. == O
The == O
supportive == O
treatments == O
such == O
as == O
oxygen == O
therapy == O
, == O
con == O
‐ == O
[57,58]. The supportive treatments such as oxygen  therapy,  con‐ servation == O
fluid == O
management == O
, == O
and == O
the == O
use == O
of == O
broad == O
‐ == O
spectrum == O
antibi == O
‐ == O
servation fluid management, and the use of broad‐spectrum antibi‐ otics == O
to == O
treat == O
secondary == O
bacterial == O
infection == CAUSE_OF_DEATH
are == O
still == O
practiced == O
otics to treat secondary bacterial infection are still  practiced as == O
important == O
management == O
are == O
used == O
to == O
reduce == O
lung == O
inflammation == O
as  important  management  are  used  to reduce lung inflammation [ == O
59 == NUMBER
] == O
. == O
Some == O
of == O
the == O
drugs == CRIMINAL_CHARGE
such == O
as == O
oseltamivir == O
, == O
lopinavir == O
/ == O
ritonavir == O
, == O
[59]. Some of the drugs such as oseltamivir, lopinavir/ritonavir, nucleoside == O
analogs == O
, == O
neuraminidase == O
inhibitors == O
, == O
remdesivir == O
, == O
umifen == O
‐ == O
nucleoside analogs, neuraminidase inhibitors, remdesivir, umifen‐ ovir == O
, == O
tenofovir == O
disoproxil == O
and == O
lamivudine == O
( == O
inhibitors == O
) == O
, == O
chloro == O
‐ == O
ovir, tenofovir disoproxil and lamivudine  (inhibitors),  chloro‐ quine == O
, == O
and == O
Shufeng == PERSON
Jiedu == PERSON
or == O
Lianhua == O
Qingwen == O
capsules == O
( == O
traditional == O
quine, and Shufeng Jiedu or Lianhua Qingwen capsules (traditional medicines == O
of == O
China == COUNTRY
) == O
are == O
advised == O
to == O
treat == O
COVID19 == O
[ == O
59,6870 == NUMBER
] == O
. == O
More == O
‐ == O
medicines of China) are advised to treat COVID19 [59,6870]. More‐ over == O
, == O
some == O
inhibitors == O
such == O
as == O
3CLpro == O
( == O
3CLpro == O
‐ == O
1 == NUMBER
) == O
and == O
a == O
novel == O
vinyl == O
over, some inhibitors such as 3CLpro (3CLpro‐1) and a novel vinyl sulfone == O
protease == O
and == O
angiotensin == O
‐ == O
converting == O
enzyme == O
2 == NUMBER
( == O
ACE2 == O
) == O
‐ == O
based == O
sulfone protease and angiotensin‐converting enzyme 2 (ACE2)‐based peptide == O
showed == O
their == O
potentiality == O
against == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
[ == O
71 == NUMBER
] == O
. == O
Usual == O
‐ == O
peptide showed their potentiality against SARS‐CoV‐2 [71]. Usual‐ ly == O
, == O
drugs == CRIMINAL_CHARGE
are == O
not == O
effective == O
against == O
viral == O
diseases == CAUSE_OF_DEATH
. == O
Recently == DATE
, == O
an == O
ly, drugs are not effective against viral diseases. Recently,  an antiviral == O
drug == O
Favilavir == PERSON
has == O
approved == O
by == O
Chinas == ORGANIZATION
National == ORGANIZATION
Medical == ORGANIZATION
antiviral  drug Favilavir has approved by Chinas National Medical Products == O
Administration == O
on == O
16 == DATE
February == DATE
2020 == DATE
to == O
treat == O
COVID == O
‐ == O
19 == NUMBER
Products Administration on 16 February  2020  to  treat  COVID‐19 [ == O
72 == NUMBER
] == O
. == O
This == O
drug == O
has == O
produced == O
by == O
Zhejiang == STATE_OR_PROVINCE
Hisun == LOCATION
Pharmaceutical == LOCATION
and == O
[72]. This drug has produced by Zhejiang Hisun Pharmaceutical and marketed == O
as == O
brand == O
name == O
Avigan == PERSON
[ == O
73 == NUMBER
] == O
. == O
Current == DATE
challenges == O
of == O
marketed as  brand  name  Avigan  [73].   Current  challenges  of COVID == O
‐ == O
19 == NUMBER
in == O
Bangladesh == COUNTRY
News == O
such == O
as == O
Coronavirus == O
Outbreak == O
: == O
Screen == O
‐ == O
COVID‐19 in Bangladesh News such as Coronavirus Outbreak: Screen‐ ing == O
still == O
lax == O
at == O
Dhaka == CITY
airport == O
in == O
the == O
Daily == SET
Star == O
on == O
10 == DATE
March == DATE
2020 == DATE
ing still lax at Dhaka airport in the Daily Star on 10 March 2020 [ == O
74 == NUMBER
] == O
[74] Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 has == O
frustrated == O
the == O
governments == O
efforts == O
to == O
combat == O
the == O
deadly == O
has frustrated the  governments  efforts  to  combat  the  deadly COVID == O
‐ == O
19 == NUMBER
in == O
Bangladesh == COUNTRY
. == O
Few == O
initiatives == O
have == O
been == O
observed == O
at == O
the == O
COVID‐19 in Bangladesh. Few initiatives have been observed at the Shah == LOCATION
Jalal == LOCATION
International == LOCATION
Airport == LOCATION
, == O
such == O
as == O
the == O
setting == O
of == O
some == O
Shah Jalal International Airport, such as  the  setting  of  some thermal == O
scanners == O
to == O
check == O
the == O
realtime == O
body == O
temperature == O
of == O
the == O
thermal  scanners  to  check the realtime body temperature of the passengers == O
and == O
filling == O
up == O
a == O
health == O
declaration == O
form == O
. == O
However == O
, == O
no == O
passengers and filling up a health declaration form. However,  no disinfection == O
activities == O
and == O
none == O
of == O
the == O
confirmation == O
tests == O
by == O
disinfection  activities  and  none  of the confirmation tests by taking == O
samples == O
from == O
the == O
passengers == O
body == O
have == O
performed == O
. == O
According == O
taking samples from the passengers body have performed. According to == O
the == O
WHO == ORGANIZATION
, == O
the == O
disease == CAUSE_OF_DEATH
could == O
remain == O
asymptomatic == O
for == O
up == O
to == O
14 == NUMBER
to  the  WHO,  the disease could remain asymptomatic for up to 14 days == DURATION
. == O
Therefore == O
, == O
thermal == O
scanner == TITLE
and == O
travel == O
history == O
are == O
not == O
days. Therefore, thermal  scanner  and  travel  history  are  not enough == O
measures == O
to == O
detect == O
COVID == O
‐ == O
19 == NUMBER
among == O
the == O
passengers == O
. == O
Apart == O
enough  measures  to  detect COVID‐19 among the passengers. Apart from == O
passengers == O
scanning == O
, == O
no == O
initiatives == O
have == O
taken == O
to == O
disinfect == O
from passengers scanning, no initiatives have taken to  disinfect the == O
planes == O
and == O
luggage == O
of == O
the == O
passengers == O
. == O
There == O
is == O
a == O
misconcep == O
‐ == O
the  planes and luggage of the passengers.  There is a misconcep‐ tion == O
among == O
the == O
people == O
of == O
Bangladesh == COUNTRY
that == O
the == O
disease == CAUSE_OF_DEATH
would == O
not == O
tion among the people of Bangladesh that the  disease  would  not sustain == O
in == O
the == O
country == O
due == O
to == O
the == O
onset == O
of == O
summer == DATE
when == O
the == O
tem == O
‐ == O
sustain  in  the country due to the onset of summer when the tem‐ perature == O
would == O
remain == O
above == O
30C == O
. == O
However == O
, == O
the == O
recent == O
study == O
re == O
‐ == O
perature would remain above 30C. However, the  recent  study  re‐ ported == O
that == O
temperature == O
does == O
not == O
change == O
the == O
transmission == O
of == O
ported  that  temperature  does  not  change  the transmission of COVID == O
‐ == O
19 == NUMBER
[ == O
46 == NUMBER
] == O
; == O
unlike == O
the == O
SARS == MISC
virus == O
, == O
there == O
is == O
no == O
evidence == O
that == O
COVID‐19 [46]; unlike the SARS virus, there is no  evidence  that the == O
outbreak == O
of == O
COVID == O
‐ == O
19 == NUMBER
would == O
be == O
reduced == O
at == O
higher == O
temperature == O
the  outbreak  of COVID‐19 would be reduced at higher temperature [ == O
75 == NUMBER
] == O
. == O
Other == O
challenges == O
are == O
( == O
i == O
) == O
lack == O
of == O
laboratory == O
facilities == O
for == O
[75].  Other challenges are (i) lack of laboratory facilities for the == O
early == O
detection == O
of == O
the == O
disease == CAUSE_OF_DEATH
, == O
( == O
ii == O
) == O
scarcity == O
of == O
medical == O
sup == O
‐ == O
the early detection of the disease, (ii) scarcity of medical sup‐ plies == O
, == O
such == O
as == O
surgical == O
masks == O
and == O
goggles == O
, == O
( == O
iv == O
) == O
lack == O
of == O
personal == O
plies, such as surgical masks and goggles, (iv) lack of  personal protective == O
equipment == O
( == O
PPE == O
) == O
for == O
healthcare == O
personnel == O
, == O
( == O
iv == O
) == O
asymp == O
‐ == O
protective  equipment (PPE) for healthcare personnel, (iv) asymp‐ tomatic == O
transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
which == O
could == O
challenge == O
the == O
man == O
‐ == O
tomatic transmission of COVID‐19 which could challenge  the  man‐ agement == O
strategies == O
at == O
risk == O
[ == O
41 == NUMBER
] == O
, == O
( == O
v == O
) == O
lack == O
of == O
quarantine == O
facili == O
‐ == O
agement  strategies  at risk [41], (v) lack of quarantine facili‐ ties == O
at == O
the == O
hospitals == O
, == O
( == O
v == O
) == O
it == O
is == O
very == O
unfortunate == O
that == O
a == O
good == O
ties at the hospitals, (v) it is very  unfortunate  that  a  good number == O
of == O
people == O
of == O
Bangladesh == COUNTRY
are == O
not == O
maintaining == O
good == O
hygiene == O
number  of  people of Bangladesh are not maintaining good hygiene and == O
sanitation == O
practices == O
, == O
and == O
( == O
vi == O
) == O
until == O
now == DATE
, == O
no == O
specific == O
drugs == CRIMINAL_CHARGE
and sanitation practices, and (vi) until now, no  specific  drugs or == O
vaccines == O
have == O
been == O
proven == O
effective == O
against == O
COVID == O
‐ == O
19 == NUMBER
. == O
Global == O
‐ == O
or vaccines have been proven effective against COVID‐19.  Global‐ ly == O
, == O
as == O
there == O
are == O
no == O
vaccines == O
discovered == O
against == O
novel == O
coronavirus == O
ly, as there are no vaccines discovered against novel coronavirus disease == CAUSE_OF_DEATH
COVID == O
‐ == O
19 == NUMBER
; == O
therefore == O
, == O
prevention == O
and == O
management == O
are == O
the == O
disease  COVID‐19;  therefore,  prevention and management are the best == O
ways == O
to == O
tackle == O
this == O
deadly == O
disease == CAUSE_OF_DEATH
. == O
By == O
comparing == O
the == O
global == O
best ways to tackle this deadly disease. By comparing the  global outbreak == O
, == O
confirmed == O
cases == O
are == O
only == O
0.003 == PERCENT
% == PERCENT
in == O
Bangladesh == COUNTRY
[ == O
8 == NUMBER
] == O
. == O
How == O
‐ == O
outbreak, confirmed cases are only 0.003% in Bangladesh [8]. How‐ ever == O
, == O
stern == O
actions == O
should == O
be == O
taken == O
immediately == O
so == O
that == O
further == O
ever, stern actions should be taken immediately so  that  further penetration == O
of == O
any == O
case == O
is == O
not == O
possible == O
through == O
the == O
land == O
‐ == O
, == O
sea == O
‐ == O
, == O
penetration  of any case is not possible through the land‐, sea‐, and == O
airports == O
. == O
Nationally == O
, == O
public == O
awareness == O
is == O
the == O
crucial == O
factor == O
and airports. Nationally, public awareness is the crucial  factor in == O
protecting == O
this == O
disease == CAUSE_OF_DEATH
. == O
The == O
health == O
officials == O
, == O
doctors == O
, == O
and == O
to == O
in protecting this disease. The health officials, doctors, and to educate == O
them == O
about == O
the == O
protection == O
and == O
safety == O
measures == O
against == O
educate them about the protection  and  safety  measures  against COVID == O
‐ == O
19 == NUMBER
. == O
Early == O
and == O
quick == O
detection == O
are == O
essential == O
measures == O
to == O
COVID‐19.   Early  and  quick detection are essential measures to stop == O
the == O
transmission == O
of == O
COVID == O
‐ == O
19 == NUMBER
. == O
The == O
diagnostic == O
facilities == O
of == O
stop the transmission of COVID‐19. The diagnostic  facilities  of Bangladesh == COUNTRY
should == O
be == O
improved == O
by == O
providing == O
the == O
detection == O
facili == O
‐ == O
Bangladesh  should be improved by providing the detection facili‐ ties == O
at == O
all == O
the == O
divisional == O
, == O
district == O
, == O
and == O
upazilla == O
hospitals == O
. == O
ties at all the divisional,  district,  and  upazilla  hospitals. Once == DATE
a == O
new == O
case == O
is == O
detected == O
, == O
he == O
should == O
be == O
isolated == O
immediately == O
. == O
Once  a  new case is detected, he should be isolated immediately. Some == O
general == TITLE
recommendations == O
are == O
suggested == O
as == O
( == O
i == O
) == O
as == O
per == O
the == O
WHOs == O
Some general recommendations are suggested as (i) as per the WHOs guidelines == O
[ == O
23 == NUMBER
] == O
, == O
hand == O
hygiene == O
must == O
be == O
maintained == O
by == O
cleaning == O
guidelines  [23],  hand  hygiene  must  be maintained by cleaning hands == O
with == O
soap == O
and == O
water == O
for == O
at == DURATION
least == DURATION
20 == DURATION
seconds == DURATION
or == O
using == O
alco == O
‐ == O
hands with soap and water for at least 20 seconds or using  alco‐ hol == O
‐ == O
based == O
hand == O
sanitizer == O
, == O
( == O
ii == O
) == O
avoid == O
contact == O
hands == O
with == O
eyes == O
, == O
hol‐based  hand  sanitizer,  (ii)  avoid contact hands with eyes, nose == O
, == O
and == O
mouth == O
, == O
( == O
iii == O
) == O
the == O
use == O
of == O
disposable == O
tissues == O
or == O
clothing == O
nose, and mouth, (iii) the use of disposable tissues or  clothing when == O
coughs == O
and == O
sneezes == O
, == O
( == O
iv == O
) == O
health == O
personnel == O
must == O
ensure == O
PPE == O
when  coughs  and  sneezes, (iv) health personnel must ensure PPE while == O
working == O
, == O
( == O
v == O
) == O
avoid == O
interpersonal == O
contact == O
such == O
as == O
kissing == O
, == O
while working, (v) avoid interpersonal contact such  as  kissing, handshaking == O
, == O
and == O
so == O
on == O
, == O
( == O
vi == O
) == O
avoid == O
mass == O
gathering == O
and == O
seek == O
medi == O
‐ == O
handshaking,  and so on, (vi) avoid mass gathering and seek medi‐ cal == O
care == O
when == O
anyone == O
feels == O
fever == CAUSE_OF_DEATH
, == O
cough == O
, == O
and == O
difficulty == O
breath == O
‐ == O
cal care when anyone feels fever, cough, and  difficulty  breath‐ ing == O
, == O
( == O
ix == O
) == O
once == DATE
a == O
person == O
is == O
detected == O
positive == O
with == O
COVID == O
‐ == O
19 == NUMBER
, == O
he == O
ing,  (ix)  once  a person is detected positive with COVID‐19, he must == O
be == O
isolated == O
for == O
at == DURATION
least == DURATION
14 == DURATION
days == DURATION
, == O
( == O
x == O
) == O
operation == O
of == O
public == O
must be isolated for at least 14 days, (x)  operation  of  public transportations == O
such == O
as == O
local == O
buses == O
, == O
launches == O
, == O
and == O
trains == O
should == O
transportations  such as local buses, launches, and trains should be == O
limited == O
for == O
23 == DURATION
weeks == DURATION
, == O
and == O
( == O
xi == O
) == O
passengers == O
return == O
from == O
abroad == O
be limited for 23 weeks, and (xi) passengers return  from  abroad should == O
be == O
self == O
‐ == O
quarantined == O
for == O
2 == DURATION
weeks == DURATION
. == O
Specific == O
recommendations == O
should be self‐quarantined for 2 weeks.  Specific recommendations to == O
the == O
government == O
are == O
as == O
( == O
i == O
) == O
Apart == O
from == O
European == NATIONALITY
to the government  are  as  (i)             Apart  from  European flights == O
, == O
passengers == O
from == O
other == O
infected == O
countries == O
such == O
as == O
China == COUNTRY
, == O
flights,  passengers from other infected countries such as China, the == O
should == O
undergo == O
extensive == O
screening == O
and == O
, == O
if == O
possible == O
, == O
should == O
the should undergo extensive screening and, if  possible,  should be == O
kept == O
in == O
force == O
isolation == O
for == O
2 == DURATION
weeks == DURATION
. == O
Besides == O
, == O
the == O
planes == O
and == O
be  kept  in force isolation for 2 weeks. Besides, the planes and luggage == O
arriving == O
from == O
these == O
countries == O
should == O
be == O
disinfected == O
. == O
luggage arriving from  these  countries  should  be  disinfected. Compulsory == O
screening == O
of == O
passengers == O
must == O
be == O
maintained == O
at == O
all == O
the == O
Compulsory  screening of passengers must be maintained at all the entry == O
points == O
of == O
Bangladesh == COUNTRY
. == O
( == O
ii == O
) == O
Collaborative == O
research == O
be == O
‐ == O
entry points of Bangladesh.  (ii)    Collaborative  research  be‐ tween == O
the == O
WHO == ORGANIZATION
and == O
government == O
or == O
nongovernment == O
organizations == O
tween  the  WHO  and  government  or  nongovernment organizations should == O
be == O
carried == O
out == O
immediately == O
to == O
develop == O
a == O
vaccine == O
for == O
SARS == O
‐ == O
should be carried out immediately to develop a vaccine for  SARS‐ CoV == O
‐ == O
2 == NUMBER
. == O
( == O
iii == O
) == O
Providing == O
sufficient == O
funds == O
to == O
conduct == O
research == O
on == O
CoV‐2.  (iii)   Providing sufficient funds to conduct research on epidemiology == O
, == O
surveillance == O
, == O
and == O
management == O
of == O
COVID == O
‐ == O
19 == NUMBER
in == O
epidemiology,  surveillance,  and  management  of   COVID‐19   in Bangladesh == COUNTRY
. == O
( == O
iv == O
) == O
Frequently == O
circulate == O
the == O
news == O
of == O
public == O
Bangladesh.   (iv)    Frequently  circulate  the  news  of public awareness == O
and == O
precautions == O
about == O
COVID == O
‐ == O
19 == NUMBER
in == O
mass == O
Nothing == O
to == O
dis == O
‐ == O
awareness and precautions about COVID‐19 in mass Nothing to  dis‐ close == O
. == O
Conflict == O
of == O
interests == O
Mohammad == PERSON
Shah == PERSON
Alam == PERSON
was == O
involved == O
in == O
close.   Conflict of interests Mohammad Shah Alam was involved in the == O
planning == O
and == O
the planning and Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam et al./ J. Adv. Vet. Anim. Res., 7(2):  198208,  June  2020 Nazmul == PERSON
Hussain == PERSON
Nazir == PERSON
and == O
Md == STATE_OR_PROVINCE
. == O
Abdullahil == PERSON
Baki == PERSON
Bhuiyan == PERSON
Beaudette == PERSON
Nazmul  Hussain  Nazir  and Md. Abdullahil Baki Bhuiyan Beaudette FR == O
, == O
Hudson == ORGANIZATION
CB == ORGANIZATION
. == O
Cultivation == O
of == O
the == O
virus == O
of == O
infectious == O
bronchitis == CAUSE_OF_DEATH
. == O
FR, Hudson CB. Cultivation of the virus of infectious bronchitis. J == O
Am == O
Vet == O
Med == O
Assoc == O
1937 == DATE
; == O
90:5160 == NUMBER
. == O
Wang == PERSON
W == PERSON
, == O
Lin == PERSON
XD == O
, == O
Guo == PERSON
WP == O
, == O
Zhou == PERSON
J  Am  Vet Med Assoc 1937; 90:5160.  Wang W, Lin XD, Guo WP, Zhou RH == O
, == O
Wang == PERSON
MR == PERSON
, == O
Wang == O
CQ == O
et == O
al == O
. == O
Discovery == O
, == O
diversity == O
and == O
evolution == O
RH, Wang MR, Wang CQ et al.  Discovery, diversity  and  evolution of == O
novel == O
coronaviruses == O
sampled == O
Gaunt == O
ER == O
, == O
Hardie == PERSON
A == O
, == O
Claas == ORGANIZATION
EC == ORGANIZATION
, == O
Sim == PERSON
‐ == PERSON
of novel coronaviruses sampled Gaunt ER, Hardie A, Claas EC, Sim‐ monds == O
P == O
, == O
Templeton == ORGANIZATION
KE == ORGANIZATION
. == O
Epidemiology == O
and == O
clinical == O
presentations == O
monds P, Templeton KE.  Epidemiology and  clinical  presentations of == O
the == O
four == NUMBER
human == O
coronaviruses == O
229E == O
, == O
HKU1 == O
, == O
NL63 == O
, == O
and == O
OC43 == O
de == O
‐ == O
of  the  four  human coronaviruses 229E, HKU1, NL63, and OC43 de‐ tected == O
over == O
3 == DURATION
years == DURATION
using == O
a == O
novel == O
multiplex == O
real == O
‐ == O
time == O
PCR == O
method == O
. == O
tected over 3 years using a novel multiplex real‐time PCR method. J == O
Clin == O
Microbiol == O
2010 == DATE
; == O
Kahn == PERSON
JS == O
, == O
McIntosh == PERSON
K. == PERSON
History == PERSON
and == O
recent == O
J  Clin  Microbiol  2010; Kahn JS, McIntosh K. History and recent advances == O
in == O
coronavirus == O
Lin == PERSON
S == PERSON
, == O
Lee == PERSON
CK == PERSON
, == O
Lee == PERSON
SY == PERSON
, == O
Kao == ORGANIZATION
CL == ORGANIZATION
, == O
Lin == PERSON
CW == PERSON
, == O
advances in coronavirus Lin S, Lee CK, Lee SY, Kao  CL,  Lin  CW, Wang == ORGANIZATION
AB == ORGANIZATION
, == O
et == O
al == O
. == O
Surface == O
ultrastructure == O
of == O
SARS == O
coronavirus == O
re == O
‐ == O
Wang  AB,  et  al. Surface ultrastructure of SARS coronavirus re‐ vealed == O
by == O
atomic == O
force == O
Centers == ORGANIZATION
for == ORGANIZATION
Disease == ORGANIZATION
Control == ORGANIZATION
and == ORGANIZATION
Prevention == ORGANIZATION
vealed by atomic force Centers for Disease Control and Prevention CDC == ORGANIZATION
. == O
Outbreak == O
of == O
severe == O
acute == O
respiratory == O
syndrome == O
‐‐ == O
worldwide == O
. == O
CDC.  Outbreak  of  severe acute respiratory syndrome‐‐worldwide. MMWR == O
‐ == O
Morbid == O
Mortal == O
W == O
2003 == DATE
; == O
52 == NUMBER
( == O
11 == NUMBER
) == O
: == O
226 == NUMBER
. == O
World == O
Health == O
Organiza == O
‐ == O
MMWR‐Morbid Mortal W 2003; 52(11): 226.  World  Health  Organiza‐ tion == O
( == O
WHO == O
) == O
. == O
Novel == O
coronavirus == O
( == O
2019 == DATE
‐ == O
nCoV == O
) == O
. == O
default == O
‐ == O
source == O
/ == O
coron == O
‐ == O
tion (WHO). Novel coronavirus (2019‐nCoV).  default‐source/coron‐ aviruse == O
/ == O
situation == O
‐ == O
re == O
‐ == O
aviruse/situation‐re‐ ports == O
/ == O
20200315 == NUMBER
‐ == O
sitrep == O
‐ == O
55 == NUMBER
‐ == O
covid == O
‐ == O
19.pdf == O
? == O
sfvrsn == O
= == O
33daa5cb_6 == NUMBER
( == O
Accessed == O
ports/20200315‐sitrep‐55‐covid‐19.pdf?sfvrsn=33daa5cb_6 (Accessed 16 == DATE
March == DATE
Ashour == PERSON
HM == O
, == O
Elkhatib == ORGANIZATION
WF == ORGANIZATION
, == O
Rahman == PERSON
MM == O
, == O
Elshabrawy == PERSON
HA == PERSON
. == O
In == O
‐ == O
16 March Ashour HM, Elkhatib WF, Rahman MM,  Elshabrawy  HA.  In‐ sights == O
into == O
the == O
Recent == O
2019 == DATE
Novel == O
Coronavirus == O
( == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
) == O
in == O
sights  into  the  Recent  2019 Novel Coronavirus (SARS‐CoV‐2) in Light == O
of == O
Past == DATE
Human == O
Coronavirus == O
Outbreaks == O
. == O
Pathogens == O
2020 == DATE
; == O
9 == NUMBER
( == O
3 == NUMBER
) == O
: == O
Light of Past Human Coronavirus Outbreaks. Pathogens 2020;  9(3): pii == O
: == O
Matoba == O
Y == O
, == O
Aoki == O
Y == O
, == O
Tanaka == PERSON
S == O
, == O
Yahagi == PERSON
K == PERSON
, == O
Shimotai == O
Y == O
, == O
Matsuzaki == PERSON
pii:  Matoba Y, Aoki Y, Tanaka S, Yahagi K, Shimotai Y, Matsuzaki Y == O
, == O
et == O
al == O
. == O
An == O
outbreak == O
of == O
human == O
coronavirus == O
OC43 == O
during == O
the == O
2014 == DATE
Y, et al. An outbreak of human coronavirus OC43 during  the  2014 2015 == DATE
influenza == CAUSE_OF_DEATH
season == O
in == O
Yamagata == LOCATION
, == O
Japan == COUNTRY
. == O
Jpn == O
J == O
Infect == O
Dis == O
2015 == DATE
; == O
2015  influenza season in Yamagata, Japan. Jpn J Infect Dis 2015; Chen == O
X == O
, == O
Chughtai == ORGANIZATION
AA == ORGANIZATION
, == O
Dyda == O
A == O
, == O
MacIntyre == O
CR == O
. == O
Comparative == O
epidemiol == O
‐ == O
Chen X, Chughtai AA, Dyda A, MacIntyre CR. Comparative epidemiol‐ ogy == O
of == O
Middle == LOCATION
East == LOCATION
respiratory == O
syndrome == O
coronavirus == O
( == O
MERSCoV == O
) == O
in == O
ogy  of Middle East respiratory syndrome coronavirus (MERSCoV) in Saudi == COUNTRY
Arabia == COUNTRY
and == O
South == COUNTRY
Korea == COUNTRY
. == O
Emerg == O
Microbes == O
Infec == O
2017 == DATE
; == O
Ahmad == PERSON
T == PERSON
, == O
Saudi Arabia and South Korea. Emerg Microbes Infec 2017; Ahmad T, Rodriguez == PERSON
‐ == O
Morales == O
AJ == O
. == O
Emergence == O
of == O
COVID == O
‐ == O
19 == NUMBER
( == O
formerly == O
Lai == O
CC == O
, == O
Rodriguez‐Morales  AJ.  Emergence  of  COVID‐19 (formerly Lai CC, Shih == PERSON
TP == O
, == O
Ko == PERSON
WC == O
, == O
Tang == O
HJ == O
, == O
Hsueh == PERSON
PR == STATE_OR_PROVINCE
. == O
Severe == O
acute == O
respiratory == O
syn == O
‐ == O
Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory  syn‐ drome == O
coronavirus == O
2 == NUMBER
( == O
SARS == O
‐ == O
CoV == O
‐ == O
2 == NUMBER
) == O
and == O
coronavirus == O
disease == CAUSE_OF_DEATH
‐ == O
2019 == DATE
drome  coronavirus  2  (SARS‐CoV‐2)  and coronavirus disease‐2019 ( == O
COVID == O
‐ == O
19 == NUMBER
) == O
: == O
the == O
epidemic == O
and == O
the == O
challenges == O
. == O
Int == PERSON
J == PERSON
Lu == PERSON
R == PERSON
, == O
Zhao == PERSON
X == PERSON
, == O
(COVID‐19): the epidemic and the challenges. Int J Lu R, Zhao  X, Li == PERSON
J == PERSON
, == O
Niu == PERSON
P == O
, == O
Yang == PERSON
B == PERSON
, == O
Wu == PERSON
H == PERSON
, == O
et == O
al == O
. == O
Genomic == O
characterisation == O
and == O
Li  J,  Niu  P, Yang B, Wu H, et al. Genomic characterisation and epidemiology == O
of == O
2019 == DATE
novel == O
coronavirus == O
: == O
implications == O
for == O
virus == O
epidemiology of 2019 novel coronavirus:  implications  for  virus origins == O
and == O
receptor == O
binding == O
. == O
Lancet == O
2020 == DATE
; == O
395 == NUMBER
( == O
10224 == NUMBER
) == O
: == O
565 == NUMBER
Jiang == PERSON
origins  and  receptor binding. Lancet 2020; 395(10224):565 Jiang S == O
, == O
Du == PERSON
L == PERSON
, == O
Shi == O
Z. == O
2020 == DATE
. == O
An == O
emerging == O
coronavirus == O
causing == O
pneumonia == CAUSE_OF_DEATH
S, Du L, Shi Z. 2020. An emerging coronavirus  causing  pneumonia outbreak == O
in == O
Wuhan == CITY
, == O
China == COUNTRY
: == O
calling == O
for == O
developing == O
therapeutic == O
and == O
outbreak  in Wuhan, China: calling for developing therapeutic and prophylactic == O
strategies == O
. == O
Emerg == O
Microbes == O
Infec == O
2020 == DATE
; == O
Kim == PERSON
JY == PERSON
, == O
Choe == PERSON
prophylactic strategies. Emerg Microbes Infec 2020; Kim JY,  Choe PG == O
, == O
Oh == O
Y == O
, == O
Oh == O
KJ == O
, == O
Kim == PERSON
J == PERSON
, == O
Park == O
SJ == O
, == O
et == O
al == O
. == O
The == O
first == ORDINAL
case == O
of == O
2019 == DATE
PG,  Oh  Y,  Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel == O
coronavirus == O
pneumonia == CAUSE_OF_DEATH
imported == O
into == O
Korea == COUNTRY
from == O
Zhu == PERSON
N == PERSON
, == O
Zhang == PERSON
novel coronavirus pneumonia imported into Korea from Zhu N, Zhang D == O
, == O
Wang == PERSON
W == PERSON
, == O
Li == PERSON
X == PERSON
, == O
Yang == PERSON
B == O
, == O
Song == O
J == O
, == O
et == O
al == O
. == O
A == O
novel == O
coronavirus == O
from == O
D,  Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients == O
with == O
pneumonia == CAUSE_OF_DEATH
in == O
China == COUNTRY
, == O
2019 == DATE
. == O
New == O
Engl == O
J == O
Med == O
World == O
patients with pneumonia in China, 2019.  New  Engl  J  Med  World Health == ORGANIZATION
Organization == ORGANIZATION
( == O
WHO == O
) == O
. == O
Novel == O
Coronavirus == O
Chu == O
YK == O
, == O
Ali == PERSON
GD == O
, == O
Jia == PERSON
Health  Organization (WHO). Novel Coronavirus Chu YK, Ali GD, Jia F == O
, == O
Li == PERSON
Q == O
, == O
Kelvin == PERSON
D == PERSON
, == O
Couch == O
RC == O
, == O
et == O
al == O
. == O
The == O
SARSCoV == O
ferret == O
model == TITLE
in == O
F, Li Q, Kelvin D, Couch RC, et al. The SARSCoV ferret  model  in an == O
infectionchallenge == O
study == O
. == O
Virology == O
2008 == DATE
; == O
Mahase == PERSON
E. == PERSON
Coron == PERSON
‐ == O
an  infectionchallenge  study.  Virology  2008;  Mahase E. Coron‐ avirus == O
: == O
covid == O
‐ == O
19 == NUMBER
has == O
killed == O
more == O
people == O
than == O
SARS == O
and == O
MERS == O
com == O
‐ == O
avirus: covid‐19 has killed more people than SARS and  MERS  com‐ bined == O
, == O
despite == O
lower == O
case == O
fatality == O
rate == O
. == O
BMJ == LOCATION
2020 == DATE
; == O
World == O
Health == O
bined,  despite  lower case fatality rate. BMJ 2020; World Health Organization == O
. == O
Water == O
, == O
sanitation == O
, == O
hygiene == O
and == O
waste == O
management == O
for == O
Organization. Water, sanitation, hygiene and waste management for COVID == O
‐ == O
19 == NUMBER
: == O
technical == O
brief == O
, == O
03.03 == NUMBER
/ == O
2020 == DATE
( == O
No == O
. == O
The == O
Prothom == O
alo == O
. == O
DSE == ORGANIZATION
, == O
COVID‐19: technical brief, 03.03/2020 (No.  The Prothom alo. DSE, CSE == ORGANIZATION
post == O
massive == O
plunge == O
. == O
Available == O
via == O
The == O
India == ORGANIZATION
Today == ORGANIZATION
. == O
PM == O
Modis == PERSON
CSE post massive plunge. Available via The India Today. PM  Modis Dhaka == CITY
trip == O
cancelled == O
after == O
3 == NUMBER
coronavirus == O
The == O
Independent == RELIGION
. == O
Panic == O
Dhaka  trip  cancelled after 3 coronavirus The Independent. Panic buying == O
triggers == O
mask == O
, == O
sanitiser == O
crises == O
. == O
Casanova == ORGANIZATION
LM == ORGANIZATION
, == O
Jeon == PERSON
S == PERSON
, == O
Ru == O
‐ == O
buying triggers mask, sanitiser crises.  Casanova LM, Jeon S, Ru‐ tala == O
WA == STATE_OR_PROVINCE
, == O
Weber == PERSON
DJ == PERSON
, == O
Sobsey == PERSON
MD == O
. == O
Effects == O
of == O
air == O
temperature == O
and == O
rel == O
‐ == O
tala WA, Weber DJ, Sobsey MD. Effects of air temperature and rel‐ ative == O
humidity == O
on == O
coronavirus == O
survival == O
on == O
Booth == O
TF == O
, == O
Kournikakis == PERSON
ative humidity on coronavirus survival on Booth  TF,  Kournikakis B == O
, == O
Bastien == PERSON
N == O
, == O
Ho == PERSON
J == PERSON
, == O
Kobasa == PERSON
D == O
, == O
Stadnyk == O
L == O
, == O
et == O
al == O
. == O
Detection == O
of == O
air == O
‐ == O
B, Bastien N, Ho J, Kobasa D, Stadnyk L, et al. Detection of air‐ borne == O
severe == O
acute == O
respiratory == O
syndrome == O
( == O
SARS == O
) == O
coronavirus == O
and == O
borne severe acute respiratory syndrome  (SARS)  coronavirus  and environmental == O
contamination == O
in == O
SARS == O
Alghamdi == O
IG == O
, == O
Hussain == PERSON
II == PERSON
, == O
Al == O
‐ == O
environmental  contamination in SARS Alghamdi IG, Hussain II, Al‐ malki == O
SS == O
, == O
Alghamdi == PERSON
MS == STATE_OR_PROVINCE
, == O
Alghamdi == PERSON
MM == O
, == O
El == O
‐ == O
Sheemy == O
MA == STATE_OR_PROVINCE
. == O
2014 == DATE
. == O
The == O
pat == O
‐ == O
malki SS, Alghamdi MS, Alghamdi MM, El‐Sheemy MA. 2014. The  pat‐ tern == O
of == O
Middle == LOCATION
East == LOCATION
respiratory == O
syndrome == O
coronavirus == O
in == O
Saudi == NATIONALITY
tern  of  Middle  East  respiratory syndrome coronavirus in Saudi Arabia == O
: == O
a == O
descriptive == O
epidemiological == O
analysis == O
of == O
data == O
from == O
the == O
Arabia: a descriptive epidemiological analysis of data  from  the Saudi == ORGANIZATION
Ministry == ORGANIZATION
of == ORGANIZATION
Health == ORGANIZATION
. == O
Int == PERSON
J == PERSON
Gen == PERSON
Med == PERSON
Luo == PERSON
W == PERSON
, == O
Majumder == PERSON
MS == STATE_OR_PROVINCE
, == O
Liu == PERSON
Saudi  Ministry  of Health. Int J Gen Med Luo W, Majumder MS, Liu D == O
, == O
Poirier == PERSON
C == O
, == O
Mandl == ORGANIZATION
KD == ORGANIZATION
, == O
Lipsitch == O
M == O
, == O
et == O
al == O
. == O
The == O
role == O
of == O
absolute == O
D, Poirier C, Mandl KD, Lipsitch M, et al. The role  of  absolute humidity == O
on == O
transmission == O
Wang == PERSON
M == O
, == O
Jiang == PERSON
A == O
, == O
Gong == O
L == O
, == O
Luo == PERSON
L == PERSON
, == O
Guo == PERSON
W == PERSON
, == O
humidity  on  transmission Wang M, Jiang A, Gong L, Luo L, Guo W, Li == PERSON
C == PERSON
, == O
et == O
al == O
. == O
Temperature == O
significant == O
change == O
COVID == O
‐ == O
19 == NUMBER
Transmission == O
Li C, et al. Temperature significant change COVID‐19 Transmission in == O
429 == NUMBER
cities == O
. == O
medRxiv == O
in 429 cities. medRxiv Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 Huang == PERSON
C == PERSON
, == O
Wang == O
Y == O
, == O
Li == PERSON
X == PERSON
, == O
Ren == PERSON
L == PERSON
, == O
Zhao == PERSON
J == PERSON
, == O
Hu == O
Y == O
, == O
et == O
al == O
. == O
Clinical == O
fea == O
‐ == O
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical  fea‐ tures == O
of == O
patients == O
infected == O
with == O
2019 == DATE
novel == O
coronavirus == O
in == O
Wuhan == CITY
, == O
tures  of patients infected with 2019 novel coronavirus in Wuhan, Chan == RELIGION
JF == O
, == O
Yuan == PERSON
S == PERSON
, == O
Kok == PERSON
KH == O
, == O
To == ORGANIZATION
KK == ORGANIZATION
, == O
Chu == PERSON
H == PERSON
, == O
Yang == PERSON
J == PERSON
, == O
et == O
al == O
. == O
A == O
familial == O
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A  familial cluster == O
of == O
pneumonia == CAUSE_OF_DEATH
associated == O
with == O
the == O
2019 == DATE
novel == O
coronavirus == O
cluster  of  pneumonia associated with the 2019 novel coronavirus Coronavirus == O
disease == CAUSE_OF_DEATH
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
advice == O
for == O
the == O
public == O
. == O
World == O
Coronavirus disease  (COVID‐19)  advice  for  the  public.  World Health == ORGANIZATION
Organization == ORGANIZATION
, == O
Geneva == CITY
, == O
Switzerland == COUNTRY
, == O
2020 == DATE
. == O
Available == O
via == O
Health  Organization,  Geneva,  Switzerland,  2020. Available via Rothe == PERSON
C == O
, == O
Schunk == PERSON
M == O
, == O
Sothmann == O
P == O
, == O
Bretzel == PERSON
G == PERSON
, == O
Froeschl == PERSON
G == PERSON
, == O
Wallrauch == PERSON
Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl  G,  Wallrauch C == O
, == O
et == O
al == O
. == O
Transmission == O
of == O
2019nCoV == O
Infection == CAUSE_OF_DEATH
from == O
an == O
asymptomatic == O
C, et al. Transmission of 2019nCoV Infection from an asymptomatic contact == O
in == O
Germany == COUNTRY
. == O
New == O
Engl == O
J == O
Med == O
2020 == DATE
; == O
382 == NUMBER
( == O
10 == NUMBER
) == O
: == O
9701 == DATE
; == O
Huda == PERSON
ASN == O
, == O
contact in Germany. New Engl J Med 2020; 382(10):9701; Huda  ASN, Mekhilef == PERSON
S == PERSON
, == O
Ahsan == PERSON
A. == O
2014 == DATE
. == O
Biomass == O
energy == O
in == O
Bangladesh == COUNTRY
: == O
current == DATE
Mekhilef  S, Ahsan A. 2014. Biomass energy in Bangladesh: current status == O
and == O
prospects == O
. == O
Renew == O
Sust == ORGANIZATION
Energ == ORGANIZATION
Rev == ORGANIZATION
Eccles == ORGANIZATION
R == ORGANIZATION
. == O
An == O
explana == O
‐ == O
status and prospects. Renew Sust Energ Rev Eccles R. An  explana‐ tion == O
for == O
the == O
seasonality == O
of == O
acute == O
upper == O
respiratory == O
tract == O
viral == O
tion  for  the seasonality of acute upper respiratory tract viral infections == CAUSE_OF_DEATH
. == O
Acta == O
Otolaryngol == O
2002 == DATE
; == O
122:18391 == NUMBER
; == O
Kudo == PERSON
E == O
, == O
Song == O
E == O
, == O
infections. Acta Otolaryngol 2002; 122:18391;  Kudo  E,  Song  E, Yockey == PERSON
LJ == PERSON
, == O
Rakib == PERSON
T == PERSON
, == O
Wong == PERSON
PW == O
, == O
Homer == PERSON
RJ == PERSON
, == O
et == O
al == O
. == O
Low == O
ambient == O
humid == O
‐ == O
Yockey LJ, Rakib T, Wong PW, Homer RJ, et al.  Low ambient humid‐ ity == O
impairs == O
barrier == O
function == O
and == O
innate == O
resistance == O
against == O
in == O
‐ == O
ity impairs barrier function and innate  resistance  against  in‐ fluenza == O
infection == CAUSE_OF_DEATH
. == O
Proc == ORGANIZATION
Natl == ORGANIZATION
Acad == ORGANIZATION
Sci == ORGANIZATION
USA == ORGANIZATION
2019 == DATE
; == O
Peiris == PERSON
JS == O
, == O
Guan == PERSON
fluenza  infection.  Proc Natl Acad Sci USA 2019; Peiris JS, Guan Y == O
, == O
Yuen == LOCATION
KY == LOCATION
. == O
Severe == O
acute == O
respiratory == O
syndrome == O
, == O
Nat == PERSON
Verma == PERSON
GP == O
. == O
Fun == O
‐ == O
Y, Yuen KY. Severe acute respiratory syndrome, Nat Verma GP. Fun‐ damentals == O
of == O
histology == O
. == O
New == RELIGION
Age == RELIGION
International == O
Pvt == TITLE
Zhao == PERSON
J == PERSON
, == O
Zhao == PERSON
J == PERSON
, == O
damentals of histology. New Age International Pvt Zhao J, Zhao J, Van == PERSON
Rooijen == PERSON
N == PERSON
, == O
Perlman == PERSON
S. == O
Evasion == O
by == O
stealth == O
. == O
Inefficient == O
immune == O
Van Rooijen N, Perlman S. Evasion by stealth.  Inefficient immune activation == O
underlies == O
poor == O
T == O
cell == O
response == O
and == O
severe == O
disease == CAUSE_OF_DEATH
in == O
activation  underlies  poor T cell response and severe disease in SARS == O
‐ == O
CoV == O
infected == O
mice == O
. == O
PloS == O
Pathog == O
2009 == DATE
; == O
Velavan == O
TP == O
, == O
Meyer == PERSON
CG == O
. == O
SARS‐CoV infected mice. PloS Pathog 2009; Velavan TP,  Meyer  CG. The == O
COVID19 == O
epidemic == O
. == O
Trop == O
Med == O
Int == O
Zu == O
ZY == O
, == O
Jiang == PERSON
MD == STATE_OR_PROVINCE
, == O
Xu == O
PP == O
, == O
Chen == PERSON
The  COVID19  epidemic. Trop Med Int Zu ZY, Jiang MD, Xu PP, Chen W == O
, == O
Ni == O
QQ == O
, == O
Lu == ORGANIZATION
GM == ORGANIZATION
, == O
et == O
al == O
. == O
Coronavirus == O
Disease == CAUSE_OF_DEATH
2019 == DATE
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
: == O
a == O
W, Ni QQ, Lu GM, et al. Coronavirus Disease  2019  (COVID‐19):  a perspective == O
from == O
China == COUNTRY
. == O
Radiology == O
Ai == O
T == O
, == O
Yang == PERSON
Z == PERSON
, == O
Hou == PERSON
H == PERSON
, == O
Zhan == PERSON
C == PERSON
, == O
perspective  from  China.  Radiology Ai T, Yang Z, Hou H, Zhan C, Chen == O
C == O
, == O
Lv == PERSON
W == PERSON
, == O
et == O
al == O
. == O
Correlation == O
of == O
chest == O
CT == STATE_OR_PROVINCE
and == O
RT == O
‐ == O
PCR == O
testing == O
Chen C, Lv W, et al. Correlation of chest CT and  RT‐PCR  testing in == O
coronavirus == O
disease == CAUSE_OF_DEATH
2019 == DATE
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
in == O
Fang == O
Y == O
, == O
Zhang == PERSON
H == PERSON
, == O
Xie == PERSON
J == PERSON
, == O
in coronavirus disease 2019 (COVID‐19) in Fang Y, Zhang H, Xie J, Lin == PERSON
M == O
, == O
Ying == PERSON
L == PERSON
, == O
Pang == PERSON
P == O
, == O
et == O
al == O
. == O
Sensitivity == O
of == O
chest == O
CT == STATE_OR_PROVINCE
for == O
Lin M, Ying L, Pang  P,  et  al.  Sensitivity  of  chest  CT  for COVID == O
‐ == O
19 == NUMBER
: == O
comparison == O
to == O
RT == O
‐ == O
PCR == O
. == O
Radiology == O
2020 == DATE
; == O
200432 == NUMBER
; == O
Xie == PERSON
X == PERSON
, == O
COVID‐19:  comparison  to  RT‐PCR. Radiology 2020; 200432; Xie X, Zhong == PERSON
Z == PERSON
, == O
Zhao == PERSON
W == PERSON
, == O
Zheng == PERSON
C == PERSON
, == O
Wang == PERSON
F == PERSON
, == O
Liu == PERSON
J. == PERSON
Chest == PERSON
CT == STATE_OR_PROVINCE
for == O
typical == O
Zhong Z, Zhao W, Zheng C, Wang F, Liu J.  Chest  CT  for  typical 2019 == DATE
‐ == O
nCoV == O
pneumonia == CAUSE_OF_DEATH
: == O
relationship == O
to == O
negative == O
RT == O
‐ == O
PCR == O
To == O
KKW == O
, == O
2019‐nCoV  pneumonia:  relationship  to  negative  RT‐PCR To KKW, Tsang == PERSON
OTY == PERSON
, == O
Yip == PERSON
CCY == O
, == O
Chan == ORGANIZATION
KH == ORGANIZATION
, == O
Wu == PERSON
TC == PERSON
, == O
Chan == ORGANIZATION
JMC == ORGANIZATION
, == O
et == O
al == O
. == O
Consistent == O
Tsang OTY, Yip CCY, Chan KH, Wu TC, Chan JMC, et al.   Consistent detection == O
of == O
2019 == DATE
novel == O
coronavirus == O
in == O
saliva == O
. == O
Clin == PERSON
Guarner == PERSON
J. == PERSON
detection  of  2019  novel coronavirus in saliva. Clin Guarner J. Three == NUMBER
emerging == O
coronaviruses == O
in == O
two == DURATION
decades == DURATION
the == O
story == O
of == O
SARS == O
, == O
Three emerging coronaviruses in two decades the  story  of  SARS, MERS == O
, == O
and == O
Now == DATE
COVID == O
‐ == O
19 == NUMBER
. == O
Am == O
J == PERSON
Clin == PERSON
Pathol == PERSON
2020 == DATE
; == O
Xiaowei == PERSON
L == PERSON
, == O
Manman == PERSON
MERS,  and Now COVID‐19. Am J Clin Pathol 2020; Xiaowei L, Manman G == O
, == O
Yizhao == PERSON
P == O
, == O
Liesu == PERSON
M == O
, == O
Shemin == PERSON
L. == PERSON
Molecular == PERSON
immune == O
pathogenesis == O
and == O
G, Yizhao P, Liesu M, Shemin L. Molecular immune pathogenesis and diagnosis == O
of == O
COVID == O
‐ == O
19 == NUMBER
. == O
J == O
Pharmaceut == O
de == O
Wit == O
E == O
, == O
van == O
Doremalen == O
N == O
, == O
diagnosis  of  COVID‐19.  J Pharmaceut de Wit E, van Doremalen N, Falzarano == PERSON
D == O
, == O
Munster == O
VJ == O
. == O
SARS == O
and == O
MERS == O
: == O
recent == O
insights == O
into == O
Falzarano D, Munster VJ. SARS  and  MERS:  recent  insights  into emerging == O
coronaviruses == O
. == O
Nat == PERSON
Zumla == PERSON
A == O
, == O
Chan == PERSON
JF == PERSON
, == O
Azhar == PERSON
EI == PERSON
, == O
Hui == O
DS == O
, == O
emerging  coronaviruses.  Nat Zumla A, Chan JF, Azhar EI, Hui DS, Yuen == LOCATION
KY == LOCATION
. == O
Coronaviruses == MISC
‐ == O
drug == O
The == O
SARS == O
, == O
MERS == O
and == O
novel == O
coron == O
‐ == O
Yuen KY. Coronaviruses ‐ drug The SARS,  MERS  and  novel  coron‐ avirus == O
( == O
COVID == O
‐ == O
19 == NUMBER
) == O
epidemics == O
, == O
the == O
newest == O
and == O
biggest == O
global == O
health == O
avirus (COVID‐19) epidemics, the newest and biggest global health threats == O
: == O
what == O
lessons == O
have == O
Yeo == PERSON
C == PERSON
, == O
Kaushal == PERSON
S == PERSON
, == O
Yeo == PERSON
D. == PERSON
Enteric == PERSON
in == O
‐ == O
threats: what lessons have Yeo C, Kaushal S, Yeo D.  Enteric  in‐ volvement == O
of == O
coronaviruses == O
: == O
is == O
faecaloral == O
transmission == O
of == O
SARS == O
‐ == O
volvement  of  coronaviruses: is faecaloral transmission of SARS‐ CoV == O
‐ == O
2 == NUMBER
possible == O
? == O
Zaki == PERSON
AM == O
, == O
van == O
Boheemen == PERSON
S == PERSON
, == O
Bestebroer == PERSON
TM == PERSON
, == O
Oster == PERSON
‐ == O
CoV‐2 possible?  Zaki AM, van Boheemen S, Bestebroer  TM,  Oster‐ haus == O
AD == O
, == O
Fouchier == O
RA == O
. == O
Isolation == O
of == O
a == O
novel == O
coronavirus == O
from == O
a == O
man == O
haus AD, Fouchier RA. Isolation of a novel coronavirus from a man with == O
pneumonia == CAUSE_OF_DEATH
in == O
n == O
e == O
w == O
s == O
‐ == O
re == O
l == O
e == O
a == O
s == O
e == O
s == O
/ == O
n == O
i == O
h == O
‐ == O
c == O
l == O
i == O
n == O
i == O
c == O
with pneumonia in n e w s ‐ re l e a s e s / n i h ‐ c l i n i  c a == O
l == O
‐ == O
t == O
r == O
i == O
a == O
l == O
‐ == O
i == O
nve == O
s == O
t == O
i == NUMBER
g == O
a == O
t == O
i == O
o == O
n == O
a == O
l == O
‐ == O
va == O
c == O
cine == O
‐ == O
a  l  ‐  t  r  i  a  l ‐ i nve s t i g a t i o n a l ‐ va c cine‐ covid == O
‐ == O
19 == NUMBER
‐ == O
begins == O
( == O
Accessed == O
16 == DATE
March == DATE
2020 == DATE
) == O
. == O
Riou == PERSON
J == PERSON
, == O
Althaus == PERSON
CL == O
. == O
covid‐19‐begins (Accessed 16 March 2020).  Riou  J,  Althaus  CL. Pattern == O
of == O
early == O
human == O
‐ == O
to == O
‐ == O
human == O
transmission == O
of == O
Wuhan == CITY
2019 == DATE
novel == O
Pattern  of early human‐to‐human transmission of Wuhan 2019 novel coronavirus == O
( == O
2019nCoV == O
) == O
, == O
December == DATE
2019 == DATE
European == NATIONALITY
Centre == O
for == O
Disease == CAUSE_OF_DEATH
coronavirus (2019nCoV), December 2019 European Centre for Disease Prevention == O
and == O
Control == ORGANIZATION
( == O
ECDC == ORGANIZATION
) == O
Technical == O
report == O
. == O
Infection == CAUSE_OF_DEATH
preven == O
‐ == O
Prevention and Control (ECDC) Technical report. Infection preven‐ tion == O
and == O
control == O
for == O
the == O
care == O
of == O
patients == O
with == O
2019 == DATE
‐ == O
nCoV == O
in == O
tion and control for the  care  of  patients  with  2019‐nCoV  in healthcare == O
settings == O
. == O
Available == O
via == O
nove == O
‐ == O
coronavirus == O
‐ == O
infection == CAUSE_OF_DEATH
‐ == O
healthcare  settings.  Available  via nove‐coronavirus‐infection‐ prevention == O
‐ == O
controlpatients == O
‐ == O
healthcare == O
‐ == O
settings.pdf == O
( == O
Accessed == O
12 == NUMBER
prevention‐controlpatients‐healthcare‐settings.pdf  (Accessed  12 February == DATE
2020 == DATE
) == O
. == O
Li == O
Q == O
, == O
Guan == PERSON
X == PERSON
, == O
Wu == PERSON
P == O
, == O
Wang == O
X == O
, == O
Zhou == PERSON
L == PERSON
, == O
Tong == O
Y == O
, == O
et == O
February  2020).   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al == O
. == O
Early == O
transmission == O
dynamics == O
in == O
Wuhan == CITY
, == O
China == COUNTRY
, == O
of == O
Novel == O
Coron == O
‐ == O
al. Early transmission dynamics in Wuhan, China, of Novel  Coron‐ avirus == O
‐ == O
Infected == O
Amodio == O
E == O
, == O
Vitale == PERSON
F == O
, == O
Cimino == PERSON
L == O
, == O
Casuccio == O
A == O
, == O
Tramuto == PERSON
avirus‐Infected Amodio E, Vitale F, Cimino L, Casuccio A, Tramuto F. == O
Outbreak == O
of == O
Novel == O
Coronavirus == O
( == O
SARS == O
‐ == O
Cov == O
‐ == O
2 == NUMBER
) == O
: == O
First == ORDINAL
evidences == O
F. Outbreak of Novel Coronavirus  (SARS‐Cov‐2):  First  evidences from == O
international == O
scientific == O
literature == O
and == O
pending == O
questions == O
. == O
from  international  scientific literature and pending questions. Healthcare == ORGANIZATION
Lu == ORGANIZATION
H. == ORGANIZATION
Drug == ORGANIZATION
treatment == O
options == O
for == O
the == O
2019 == DATE
‐ == O
new == O
coron == O
‐ == O
Healthcare Lu H. Drug treatment options for the  2019‐new  coron‐ avirus == O
Wang == O
M == O
, == O
Cao == PERSON
R == PERSON
, == O
Zhang == PERSON
L == PERSON
, == O
Yang == PERSON
X == PERSON
, == O
Liu == PERSON
J == PERSON
, == O
Xu == O
M == O
, == O
et == O
al == O
. == O
Remde == O
‐ == O
avirus Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remde‐ sivir == O
and == O
Wang == PERSON
L == PERSON
, == O
Shi == PERSON
W == PERSON
, == O
Joyce == PERSON
MG == PERSON
, == O
Modjarrad == PERSON
K == PERSON
, == O
Zhang == PERSON
Y == PERSON
, == O
Leung == PERSON
K == PERSON
, == O
sivir and Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et == O
al == O
. == O
Evaluation == O
of == O
candidate == TITLE
vaccine == O
approaches == O
for == O
MERS == O
‐ == O
CoV == O
. == O
et  al.  Evaluation of candidate vaccine approaches for MERS‐CoV. Morse == ORGANIZATION
JS == ORGANIZATION
, == O
Lalonde == PERSON
T == O
, == O
Xu == PERSON
S == PERSON
, == O
Liu == PERSON
WR == O
. == O
Learning == O
from == O
the == DATE
past == DATE
: == O
possi == O
‐ == O
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possi‐ ble == O
urgent == O
prevention == O
and == O
treatment == O
options == O
for == O
severe == O
acute == O
ble urgent prevention and treatment options for severe acute Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam  et  al./  J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020 respiratory == CAUSE_OF_DEATH
infections == CAUSE_OF_DEATH
caused == O
by == O
2019nCoV == O
. == O
Chembiochem == O
2020 == DATE
; == O
Wang == PERSON
respiratory infections caused by 2019nCoV. Chembiochem 2020; Wang M == O
, == O
Jiang == PERSON
A == O
, == O
Gong == O
L == O
, == O
Luo == PERSON
L == PERSON
, == O
Guo == PERSON
W == PERSON
, == O
Li == PERSON
C == PERSON
, == O
et == O
al == O
. == O
Temperature == O
sig == O
‐ == O
M,  Jiang  A, Gong L, Luo L, Guo W, Li C, et al. Temperature sig‐ nificant == O
change == O
COVID == O
‐ == O
19 == NUMBER
Transmission == O
in == O
429 == NUMBER
cities == O
. == O
medRxiv == O
nificant change COVID‐19 Transmission in 429 cities. medRxiv Alam == PERSON
et == O
al. == O
/ == O
J. == O
Adv. == O
Vet == O
. == O
Anim == O
. == O
Res. == O
, == O
7 == NUMBER
( == O
2 == NUMBER
) == O
: == O
198208 == NUMBER
, == O
June == DATE
2020 == DATE
 Alam et al./ J. Adv. Vet. Anim. Res., 7(2): 198208, June 2020                